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CHAPTER 1 
INTRODUCTION 
Oral Squamous Cell Carcinoma (OSCC) 
Head and Neck Squamous Cell Carcinoma. Head and Neck Squamous Cell Carcinoma (HNSCC) 
is the sixth most common cancer worldwide[1]. These tumors arise in the oral cavity, pharynx, 
nasal cavity, sinuses and salivary glands[2]. HNSCC has a higher incidence in men -almost two-
fold- as compared to women. This is mostly attributed to lifestyle differences, though a genetic 
predisposition, especially in persons of Asian descent, has been found[3]. Use of alcohol, chewing 
tobacco and smoking are the strongest predictors of HNSCC, especially when these risks are 
combined[4]. Other important risk factors include poor oral heath, occupational/radiation exposure 
and endemic contributions from diet, namely use of betel quid or maté[5, 6]. More recently, HPV 
status, particularly HPV-16, has been significantly correlated with HNSCC and is now known to 
be a causative agent[7, 8]. The contribution of HPV status on increasing HNSCC incidence is 
observed mostly in oropharyngeal tumors, as compared to tumors of the oral cavity, or sinuses[8]. 
It is important to note that oral cavity tumors comprise the majority of HNSCC, with reports citing 
up to 50%, many of which arise in the tongue[2, 9]. These tumors are known as Oral Squamous 
Cell Carcinoma, and will be the focus of the work presented in this text. 
OSCC etiology and pathology. OSCC is defined as cancer arising from the lips, first two-thirds of 
the tongue, buccal mucosa, gingiva, as well as the floor of the mouth and the soft/hard palate[8, 
9]. OSCC etiology is not well understood, but it is generally accepted that many OSCC arise as 
the final stage of a series of oral conditions over the course of many years, starting with leukoplakia 
and ending with carcinoma[9]. Leukoplakia is a relatively common oral lesion that presents as a 
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white raised patch that cannot be scraped away but usually self resolves[10]. Dysplasia in 
leukoplakia is uncommon, but may progress to erythroplakia, which presents as a red raised lesion 
with clearly defined borders and increased vasculature[11]. Dysplasia in erythroplakia is common 
and at biopsy have been known to be malignant in persistent/advanced cases[12]. Leuoplakia and 
erythroplakia are known precursors for OSCC, although some OSCC arise without prior lesions 
or directly from leukoplakia[13]. 
Like many other tumors, OSCC presents with varying degrees of differentiation. Patients with well 
differentiated OSCC have the best prognosis of survival compared to moderately/poorly 
differentiated OSCC[14]. Gene signatures also vary among OSCC tumors. Mutations affecting 
p53, Ras, EGFR, and p16 have all been implicated as initiators and/or drivers of OSCC[15]. Some 
mutations can be grouped based on ancestry, but it is not known whether this is correlative or 
causative. Additionally, more research is needed to delineate the feasibility of successfully 
targeting these markers in patients.  
Similar to other solid tumors, OSCC is staged according to tumor size, lymph node involvement, 
and presence of metastases. OSCC is rarely symptomatic in early stages and as such is often not 
diagnosed until Stage III[16]. Additionally, the vast majority of OSCC patients demonstrate 
immune suppression at the site of the tumor, further delaying symptoms and diagnoses[17]. While 
distant metastases best predict overall survival, invasion status remains the most important 
prognostic indicator for treatment failure and recurrence[18].  
Invasion patterns of OSCC. OSCC invasion is characterized into two main types, erosive and 
infiltrative[19]. Erosive invasion presents pathologically as an invasive front, where tumor cells 
appear to a uniform front with a clear line of demarcation between the tumor and the host 
stroma[18, 19]. Molecularly, OSCC tumors with erosive invasion express high levels of cell to cell 
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adhesion proteins that are known to be associated with a less aggressive tumor cell phenotype, 
more indicative of epithelial cells[20, 21]. In contrast, infiltrative invasion presents pathologically 
as “finger-like” projects into surrounding tissue[19]. Histologically, individual as well as small 
clusters of tumors are observed ahead of the tumor front and can invade independently of the main 
tumor mass[22, 23]. Unlike single cell metastasis, these clusters can remain bound in groups, and 
are thought to contribute to secondary tumors, relapse, recurrence and local/distance 
metastases[23]. Molecularly, OSCC tumors with infiltrative invasion are known to be associated 
with a more aggressive tumor cell phenotype, indicative of mesenchymal cells. Patients whose 
tumors invade in an infiltrative manner respond less favorably to treatment and have less positive 
outcomes[24]. 
Current OSCC treatments. Unfortunately, OSCC treatment options have not significantly 
changed for almost 30 years[25]. Surgical resection remains the primary treatment option for 
OSCC, followed by radiation therapy[26]. Adjuvant treatments, such as platinum-based 
chemotherapy and hydroxyurea, are also available[27]. Most recently, the first and only targeted 
treatment for OSCC was FDA approved. This therapy, called Cetuximab, is a humanized anti-
EGFR antibody and is used alone to treat metastatic disease, or in combination with other 
treatments for advanced or recurrent disease[28]. Nearly 75% of HNSCC overexpress EGFR, 
making it a suitable target for Cetuximab[29]. Unfortunately, many advanced stage tumors treated 
with Cetuximab quickly develop resistance which leads to patient relapse[30]. This is especially 
evident if local metastases to the lymph nodes and/or mandible are present.  
OSCC recurrence and survival. The current therapies available for HNSCC patients remain 
limited, and over 40% of OSCC patients suffer from tumor relapse and recurrence after 
treatment[31]. OSCC patients whose tumors recur have poor prognoses and significantly lower 
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rates of overall survival[32, 33]. While the five-year survival rates of all OSCC patients is almost 
55%, patients who recur have 5-year survival rates of only 30%, while patients without recurrence 
have upwards of an 80% 5-year survival rate[33]. 
Bone Biology 
Physiological bone remodeling. Post-pubescent skeletons undergo constant, albeit low levels of 
remodeling. The two main cell types that maintain bone homeostasis are osteoblasts and 
osteoclasts. Osteoblasts are differentiated bone forming cells derived from mesenchymal stem 
cells, while osteoclasts are differentiated bone resorbing cells derived from monocytes. These cell 
populations have directly opposing functions that regulate one another in a tightly controlled 
feedback loop[34]. Osteoblasts express receptor activator of NFkB ligand (RANKL) on their cell 
surface which binds to RANK on pre-osteoclasts and facilitates their differentiation. As these cells 
differentiate, they fuse into large multinucleated cells. Differentiated osteoclasts secrete 
metalloproteinase enzymes that are tartrate resistant, and are known as tartrate resistant acid 
phosphatase (TRAP) positive cells[35]. Other hallmarks of a functional osteoclast include a "zone 
of attachment" or sealing zone, where the plasma membrane of the cell adheres to the bone surface 
through use of integrin mediated podosomes and a resorption pit, the space directly under the 
osteoclast. The ruffled border, which increases the surface area of the cell that can directly contact 
the bone, as well as Cathepsin K secretion are also required for resorption. Cathepsin K is a 
protease known to catabolize collagen as well as elastin. Combined with the acidic gradient 
produced in the resorption pit, TRAP, Cathepsin K, and other secreted enzymes, such as matrix 
metalloproteinases (MMPs) degrade the bone ECM, allowing dissolution of the inorganic 
component of bone, hydroxyapatite[36]. 
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Importantly, bone resorption releases and activates large amounts of growth factors and cytokines, 
which are normally sequestered in the ECM. These released signaling molecules have several 
effects, including contributing to osteoblastogenesis and inducing osteoprotegerin (OPG) 
expression. OPG is a soluble receptor for RANKL, known as a decoy receptor because it binds 
free RANKL and therefore blocks RANK/RANKL binding, thus preventing further 
osteoclastogenesis. This coupling of osteoblast activity to osteoclast activity allows for balanced 
levels of bone remodeling, where bone is resorbed at about the same rate that it is made[37].  
During development, both growth and ossification of the skeletal system is achieved largely via 
Hedgehog (Hh) signaling (Figure 1). Hh signaling is a highly conserved morphogen-based 
signaling pathway consisting of the activating receptor, Smoothened (Smo), and three ligands, 
Sonic Hh (Shh), Indian Hh (Ihh) and Desert Hh (Dhh). The receptor Patched (Ptch) is inhibitory, 
and downregulates Hh signaling. Early in development, cellular patterning of the limb bud is 
controlled predominantly by Shh. Acting as a classical morphogen, secretion of Shh forms a spatial 
and temporal gradient which controls cellular differentiation, polarization, and proliferation[38]. 
In contrast, Ihh is the predominant ligand governing Hh signaling for its role in bone formation. 
Proper endochondral ossification is essential for long bone formation. Ihh controls endochondral 
ossification through a dynamic feedback loop that also controls growth plate development[39]. In 
this process, Ihh secretion from pre-hypertrophic chondrocytes at the ends of the bones induces 
expression of parathyroid hormone-related protein (PTHrP) in periarticular chondrocytes[40-42]. 
PTHrP is secreted and diffuses along the growth plate, which increases chondrocyte proliferation 
in the growth plate region, and induces them to deposits large amounts of collagenous extra-
cellular matrix (ECM), extending the length of the developing bone. Beyond this region, levels of 
PTHrP drop and chondrocytes no longer proliferate but instead undergo hypertrophy and then 
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apoptosis[43]. Following, the resulting matrix and empty space is invaded by vasculature which is 
followed by osteoblast mediated mineralization, completing ossification.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Canonical Hedgehog signaling in mammals is ligand dependent. (A) In the 
absence of Hh ligands, Ptch accumulates in the primary cilium and inhibits the function 
of Smo. Ptch facilitates the activation of several kinases (CK1, PKA, GSK3), at the base 
of the primary cilium, which differentially phosphorylate Gli protein. This can lead to 
complete degradation of Gli protein by the proteasome, as well as partial cleavage of Gli2 
and Gli3. Partially cleaved Gli is translocated to the nucleus and functions as a 
transcriptional repressor for Hh target genes. (B) In the presence of Hh ligands, Shh, Ihh, 
or Dhh binds to Ptch, which induces its lysosomal degradation. This relieves its inhibitory 
effect on Smo, which accumulates in the primary cilium and prevents degradation of Gli 
proteins. Activated Gli protein is translocated to the nucleus and functions as a 
transcriptional activator for Hh target genes. 
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Non-physiological bone remodeling. Loss of Ihh during bone development has been shown to 
have detrimental effects on bone elongation and ossification[39]. One group demonstrated that 
loss of Ihh leads to premature chondrocyte hypertrophy, resulting in significantly shortened limbs 
lacking ossification. Additionally, levels of osteoblasts were also significantly reduced[44, 45]. 
Several groups have demonstrated that Hh signaling is critical for osteoblast differentiation, which 
is important for chondrogenesis and cartilage vascularization and thus endochondral ossification 
[46-48]. Intramembranous ossification also requires Hh signaling. Ihh null mice present with 
underdeveloped calvaria that show reduced ossification[39, 49]. Work done to understand this 
phenotype has demonstrated that Ihh regulates intramembranous ossification via osteogenic 
differentiation, and to some extent, proliferation[50]. Additionally, in these models, Ihh levels 
regulate BMP2/4 expression, suggesting that these pathways cooperate to control 
intramembranous ossification[50]. These findings appear to be central to Hh signaling, as partial 
loss of Gli3, which mainly functions as a repressor for Hh signaling, leads to increased ossification 
of calvarial bone. In these mouse models, it was observed that loss of one Gli3 allele led to 
craniosynostosis of the lambdoid sutures in the skull[51, 52].  
Genetic Hh signaling defects also disrupt normal bone remodeling. Evidence for this includes the 
finding that Ptch1 deficient patients show increased bone mass due to increased osteoblast 
differentiation[53]. Conversely, in a mouse model utilizing activated Hh signaling in mature 
osteoblasts, bone density and quality were shown to be significantly reduced. This was found to 
be caused indirectly; in mature osteoblasts Hh signaling induces PTHrP expression which 
upregulates RANKL, increasing osteoclastogenesis[54]. This finding is physiologically relevant, 
as Shh is found to be upregulated in mature osteoblasts at fracture sites. Hh signaling in mature 
osteoblasts has been shown to be key for several processes, such as osteoblast proliferation and 
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differentiation, as well as healing by mediating vascularization[55-57]. Normal bone remodeling 
can also be disrupted extrinsically when Hh signaling is abnormally regulated in tumor cells that 
are also near the bone microenvironment. 
Tumor induced bone disease. Advanced stage tumors, as well as aggressive tumors have an 
increased propensity to metastasize to distant sites of the body. Along with the lung and the liver, 
the bone is a common site of metastasis, where tumors in the bone disrupt normal bone remodeling 
and cause TIBD[58]. In patients, TIBD causes bone pain, hypercalcemia, and an increased risk of 
fracture, along with reduced skeletal mass and bone lesions[59]. Many tumor types, including 
breast, prostate, and lung, metastasize to bone via the circulatory system, while other tumors such 
as head and neck cancer invade directly into the facial bones from surrounding tissues. Primary 
bone tumors, such as osteosarcoma and multiple myeloma, also cause bone disease. While the 
molecular mechanisms controlling bone-disease varies by tumor type, all of the above-mentioned 
tumors dysregulate normal bone remodeling and induce excessive bone resorption in a process 
coined “The Vicious Cycle”[60]. In the vicious cycle, tumor cells that arrive at the bone 
microenvironment respond to chemical and physical cues by secreting factors that stimulate bone 
resorption. Cytokines such TGFβ and BMP present due to normal bone remodeling can stimulate 
tumor cells[61]. Additionally, our group has shown that the rigidity of the bone matrix can 
stimulate gene expression via mechanotransduction signaling[62]. As outlined in Figure 2, 
stimulated tumor cells, in a cell type specific manner, re-activate Hh signaling, which can be 
achieved by activating mutations in canonical Hh signaling receptor proteins Smo and Ptch, or 
non-canonically through other signaling pathways that lead to Gli activation such as TGFβ, 
PI3K/AKT, ERK and others. Increased Gli levels lead to expression and secretion of parathyroid 
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hormone-related protein (PTHrP), which increases RANKL production in osteoblasts, stimulating 
osteoclastogenesis.  
Additional signaling factors such as interleukins 6/8/11, and TNF-α, also increase 
osteoclastogenesis in a similar manner, but have not been shown to be directly dependent on Hh 
Figure 2. The Role of Hh Signaling in Bone (A) Hh signaling is active in normal bone remodeling and repair. 
Osteoblast derived Hh ligand activates Hh signaling cell autonomously as well as non-cell autonomously. PTHrP, 
a target of Hh signaling, is transcribed and PTHrP protein is secreted from the cell. Secreted PTHrP binds to its 
receptor PTHR on the surface of osteoblasts and activates the transcription factor CREB. RANKL, a target of 
PTHrP/PTHR signaling is expressed and RANKL protein is presented at the cell surface of osteoblasts, where it 
induces osteoclastogenesis and supports bone resorption. (B) Tumor-derived Hh signaling disrupts normal bone 
remodeling and induces TIBD. Tumor cells re-activate Hh signaling by canonical and/or non-canonical 
mechanisms, increasing Gli activity and Hh target genes. PTHrP is over expressed in these cells, and large 
amounts of PTHrP protein is secreted, which activates the PTHR receptor on osteoblasts. Following, large 
amounts of RANKL are produced by the osteoblasts, which lead to increased osteoclastogenesis and excessive 
bone resorption. 
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signaling[63-66]. Ultimately, as an increased number of osteoclasts mature and resorb bone, the 
released growth factors from the ECM further stimulate tumor cells, which causes a positive 
feedback loop. Tumor cells in the bone microenvironment uncouple osteoblast/osteoclast 
signaling, and lead to increased bone resorption as well as impair bone quality.   
In breast cancer metastases to bone, this process is mediated by Hh signaling. Using bone 
metastatic MDA-MB-231 breast cancer cells, we have shown that TGFβ stimulation increases 
expression of Gli2 and PTHrP, which controls bone destruction[66]. In an experimental model of 
metastasis, tumor cells injected intracardiacally home to the skeleton where they proliferate and 
induce bone destruction. We show that when Gli2 expression is repressed using a plasmid over-
expressing Gli2 repressor, both PTHrP expression and bone destruction are significantly 
reduced[67]. In this system, Gli activity does not seem to be regulated canonically, as bone tropic 
MDA-MB-231 cells do not express the Smo receptor nor do they respond to cyclopamine 
treatment[66].  A similar observation can be seen in malignant melanoma. Interestingly, while the 
melanoma cell lines used showed Smo and Ptch gene expression, Gli2 was found to be a 
transcriptional target of TGFβ signaling. Using 1205Lu melanoma cells that express high levels 
of Gli2, the authors showed that loss of Gli2 using shRNA led to a decreased incidence of bone 
metastases as well as smaller lesions[68]. 
Not surprisingly, primary bone tumors such as chondrosarcoma and osteosarcoma also dysregulate 
bone remodeling. Chondrosarcoma tumors originate from cartilage and are thought to arise due to 
activating mutations in Hh signaling[69]. Studies have shown that many primary chondrosarcomas 
express all canonical Hh signaling proteins, as well as PTHrP[69-73]. Using these tissues in 
primary organ cultures, one group showed that Hh signaling was constitutively active due to loss 
of PTCH1/2, activation of Smo or a combination of both. Additionally, using the Hh inhibitor, 
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triparanol, in a xenograph mouse model, the authors observed decreased proliferation, cellularity, 
and tumor size[69].  
Aberrant Hh signaling inducing TIBD is also observed in head and neck tumors. Many OSCC 
tumors show activated Hh signaling as measured by immunohistochemical staining of Hh ligands 
in patient biopsies[74]. Levels of Hh related proteins also correlate with poor prognosis[75]. This 
is observed in a subset of OSCC patients whose tumors have invaded into the mandible and begins 
to proliferate in the bone, stimulating bone destruction[19, 76]. One group in Japan demonstrated 
that loss of Shh in OSCC cells decreased tumor volume as well as bone destruction in an in vivo 
model of bone destruction[77]. Here tumor cells stably expressing shRNA against Shh were 
inoculated into the tibia of immunocompromised mice. Our group has also observed and 
demonstrated OSCC dependency on Hh signaling. We utilized an orthotopic model of mandibular 
invasion and bone destruction, where tumor cells are injected into the masseter muscle and invade 
directly through underlying tissues into the mandible. Using this model, we injected human OSCC 
cells stably expressing shRNA against Gli2 and observed that loss of Gli2 decreased both bony 
invasion and bone destruction in male athymic mice. These studies highlight the importance of Hh 
signaling on TIBD and suggest that Hh signaling components are viable targets to prevent TIBD. 
OSCC Invasion into the Mandible 
In patients with OSCC, the mandible is the primary site of TIBD. The mandible is required for 
mastication and swallowing, but also plays an important structural role in ensuring proper speech, 
and breathing.  
Anatomy of the mandible. The mandible, working with the maxilla, are load bearing bones, where 
the human jaw can generate biting forces upwards of 1,000 Newtons[78]. Mandibles contain 
mostly cortical bone, a dense, rigid, and compact bone layer that surrounds, protects, and supports 
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trabecular bone and other tissues inside bone structures. Like other bones, the mandible is 
innervated with blood vessels and nerves. The core of the mandible houses relatively small 
amounts of trabecular bone, along with bone marrow. Teeth are anchored in the mandible in the 
alveolar process, which remodels significantly over the course of a lifetime[79]. The tooth sockets 
are the primary mode of invasion by OSCC tumors into the mandible[19]. Tumors can also invade 
via nerve canals or by direct extension where tumors induce resorption at areas of bone contact[19]. 
OSCC patients whose tumors have invaded into mandibular space fare significantly worse[80]. 
Factors influencing mandibular invasion. Despite decades of research, factors influencing which 
tumors will invade bone are limited. Studies show that mandibular invasion correlates with tumor 
size as well as the site of the tumor[80]. Gingival tumors are closest in proximity to the mandible, 
and cause mandibular involvement about 50% of the time, but can be erosive or infiltrative tumors, 
which predict different outcomes for patients[19]. In contrast, the most common site of OSCC in 
patients is the tongue, which cause mandibular involvement in highly variable rates depending on 
the study (5% to 30%). It is important to note that regardless of the primary location or invasion 
status, patients whose tumors have invaded into the mandible suffer the same consequences, 
serious chronic pain, excessive bone resorption, and a significantly lower 5-year survival[80]. 
PTHrP regulation and effects. The bone resorption observed in OSCC patients with mandibular 
invasion occurs in a well characterized feedback system known as the Vicious Cycle[58]. Here, 
tumor cells that arrive at the bone microenvironment secrete factors that directly and/or indirectly 
stimulate bone resorption. There are several proteins capable of doing this, including PTHrP, 
RankL, IL-6, and TNF. PTHrP is expressed by many OSCC tumors and has been shown to be 
essential for bony invasion using syngeneic animal models[81]. PTHrP is small yet complex 
signaling protein originally identified for its role in hypercalcemia[82]. PTHrP is a highly 
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conserved gene of the PTH/PTHR gene family and has three known promoters which generates 
three isoforms (139, 141, and 173 amino acids) with differing functions[83]. The amino-terminus 
of PTHrP (Isoform 139) is secreted, and is a binding partner of PTHR, which signals through 
several pathways, including cAMP/PKA[84].  When PTHrP is transcribed without an export signal 
(Isoform 141), it remains in the cytosol and is shuttled into and out of the cell nucleus. This is 
regulated by both the cell cycle and the status of receptor signaling in the cell. Many studies report 
that intracellular PTHrP is shuttled to the nucleus in response to cell viability, and functions to 
prevent apoptosis[85-89]. The last isoform of PTHrP is least understood and is thought to signal 
completely independently of the other two isoforms. In OSCC patients, PTHrP expression 
correlates with a positive invasion status, and independently serves as a poor prognostic 
indicator[90]. 
Hedgehog signaling in OSCC. PTHrP expression is canonically regulated by Hh signaling, and 
this is also observed in many OSCC tumors[91]. In vitro, many OSCC cell lines have been shown 
to express Hh ligands, namely Shh, as well as the Hh effector proteins Gli1 and Gli2[75, 92]. Some 
studies highlight the role of aberrant Hh signaling as a driver of OSCC tumorigenesis. One study 
demonstrated that OSCC induced by the oral carcinogen 4NQO, had significantly higher levels of 
Shh, and further showed that significantly elevated levels of Shh could also be found in dysplastic 
lesions[93]. Many studies of OSCC investigate the effects of Hh signaling on promoting tumor 
progression, such as by increasing angiogenesis or by suppressing the immune compartment[18, 
94-96]. Using immunohistochemical staining, Shh expression has been found to be linked to 
invasion, as levels of Shh correlate significantly with MMP-9 expression[97, 98]. Generally, the 
implications of Hh signaling in OSCC has been limited to correlation studies using patient samples 
and data. Though these are informative in predicting prognoses and identifying relevant targets, 
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molecular mechanisms explaining Hh signaling and its effects in OSCC is still largely unstudied. 
In our studies, we investigate the effect of Hh signaling in OSCC on mediating expression of 
PTHrP, which is required for tumor invasion into bone. The Hh effector protein Gli2, is expressed 
in nine of the ten OSCC lines tested and plays a major role in tumor invasion into the bone. 
TGFβ signaling in OSCC. It is important to note that while Hh signaling is highly conserved, 
there are non-canonical mechanisms that can activate Hh signaling downstream of its receptor and 
induce expression of Hh related target genes[99].  In addition to increasing Hh components, these 
signaling systems may or may not retain their individual signal transduction profile, which makes 
understanding signaling mechanisms quite difficult. TGFβ signaling is one such signaling pathway 
that aberrantly increases Hh targets downstream of the Hh receptor, Smo[66, 67, 100]. Canonical 
TGFβ signals through dimerization and activation of TGFβ receptors, which increases 
phosphorylation of Smad2 and Smad3, which are translocated to the nucleus and increases 
expression of TGFβ target genes. In OSCC, and other tumor types, TGFβ activation increases Gli2 
transcription by directly binding to the promoter region of Gli2 and inducing expression[99]. TGFβ 
signaling in OSCC has also been shown to induce expression of c-myc (a known driver oncogene 
in OSCC), and miR-455-5p, both of which have been implicated in supporting invasion in 
OSCC[101]. Even so, there are several studies with negative and/or conflicting reports involving 
TGFβ. In a cohort of 89 clinical OSCC samples, TGFβ was not found to correlate with known 
invasion biomarkers[102]. Non-canonical TGFβ signaling, which signals through p38/MAPK, can 
also increase Hh activation and contribute to OSCC tumorigenesis. MAPK activation 
phosphorylates MEF2C, which can transcribe Gli2[99]. Additionally, p38/MAPK activation was 
found to correlate with increased cell proliferation and decreased cell apoptosis when OSCC cells 
are treated with a GABRP agonist[103]. Collectively, it is clear that the role of TGFβ on 
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modulating OSCC is specific to the context of its activation. In our system though, the direct effect 
of TGFβ on increasing Hh activation is clear in several different OSCC cell lines tested. 
Wnt signaling in OSCC. Wnt signaling is another highly conserved developmental signaling 
pathway with major roles in many organ systems including bone homeostasis, stem cell 
maintenance and cancer initiation[104, 105]. Wnt signaling is activated when Wnt ligands bind to 
and activate the Wnt receptor complex of Frizzled and LRP5/6 causing release of the Wnt effector 
protein, beta-catenin, from an inhibitory complex. Stabilized beta-catenin is then translocated to 
the nucleus and initiates transcription of target genes. There have been several studies highlighting 
Wnt target genes and/or beta-catenin as a mediator for oncogenic signaling. A recent study from 
2016 demonstrated that during oral carcinogenesis, negative regulators of Wnt are found to be 
significantly silenced by gene methylation, highlighting it as an important epigenetic modification 
in OSCC[106].  Other data stress the importance of beta-catenin and downstream targets for OSCC 
invasion and migration, independent of upstream regulation[107, 108]. We have observed similar 
findings, where Wnt activation at the levels of beta-catenin transcribes genes important for OSCC 
bony invasion, such as Gli2.  
Mechanical signaling in OSCC. Mechanical signaling is another pathway OSCC cells exploit 
during tumorigenesis and tumor progression. Mechanotransduction allows cells to sense and 
respond to changes in the ECM by converting mechanical forces into biochemical signals[109]. 
This primarily occurs through integrin signaling and subsequent downstream activation of FAK, 
Rho and ROCK and eventually leads to cytoskeletal rearrangements, activation of growth factor 
receptor signaling, and/or changes in protein trafficking and transports[110]. The oldest published 
work on OSCC ECM components have been found to be important in OSCC, especially in the 
context of OSCC invasion and metastasis[23]. For example, one group has shown that fibronectin 
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in the ECM contributes to cancer cell migration, while another group demonstrated that the ECM 
protein, thrombospondin, and increased MMP 3/9/11/13 expression via integrin signaling[22, 97, 
111]. These studies are very recent and demonstrate the novel signaling mechanisms controlling 
OSCC. Other studies demonstrate that ECM components and the resulting mechanical signaling, 
are essential for many cell processes, such as directional migration, filopodium formation, and 
single cell metastases[22, 112, 113]. Unfortunately, there have been very few studies investigating 
the mechanisms of mechanical signaling in OSCC. Most of the research done have been correlative 
studies, either in vitro or through the use of patient samples. Our group has investigated the role 
of mechanical signaling on increasing Gli2 activation in OSCC grown on ECM of differing 
rigidities. Similar to other groups, we observed changes in FAK, Rho, and ROCK in response to 
changes in ECM. Collectively, Hh, TGFβ, Wnt, and mechanical signaling all play an important 
role in regulating OSCC. 
Gli family regulation. The effector signaling molecule of Hh signaling is Gli, which is activated 
in canonical Hh signaling, but is also regulated by a number of non-canonical signaling 
mechanisms. There are three known members of the Gli family; Gli1, Gli2, and Gli3. Each Gli 
protein has specific functions, but is also known to overlap, oppose, and regulate one another in a 
context specific manner. The Gli family members are zinc finger proteins that can bind directly to 
DNA. The consensus promoter sequence is GACCACCCA-like. Gli1 is the best studied member 
of the Gli family and functions as a transcriptional activator of downstream target. Gli1 mRNA is 
constantly made and translated, but Gli1 protein is quickly degraded via ubiquitination-mediated 
proteasome degradation. When Hh signaling is activated, Gli1 protein is stabilized and very 
quickly accumulates in the cell, where it is shuttled to the primary cilium for activation in a process 
that is still very much not understood[114]. Activated Gli1 is then shuttled to the nucleus where it 
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transcribes genes important for cell cycle regulation, such as Cyclin D2, as well as Patched, which 
serves as a negative regulator of Hh signaling. 
Gli member downstream targets. Other genes regulated by Gli1 include osteopontin, neural 
proliferation differentiation control gene-1 (NPDC1), ubiquitin-specific protease -7 (USP7), and 
insulin like growth factor binding protein-6 (rIGF-6)[115]. Gli2 binds to the identical consensus 
region as Gli1, yet can be extensively regulated independently of Gli1. Gli2 mRNA expression 
can potentially be regulated by a large number of transcription factors, including members of the 
JUN/FOS signaling family, MYC, CREB, and E2F, among others[116]. Gli2 has several alternate 
start sites, which leads to five distinct isoforms, some of which require proteasome processing for 
activation[117]. Four of the isoforms function as transcriptional activators, but the remaining 
isoform encodes truncated Gli2 protein that functions as a transcriptional repressor. Activated Gli2 
transcribes Gli1 and Ptch, but can also regulate expression of HHIP1, BCL2, BMI1, SNAIL, 
SLUG, and TWIST[118]. Many of these targets serve a potential, but unstudied, role in OSCC 
tumorigenesis. It is important to note that while Gli1 and Gli2 have the potential to regulate many 
of the same targets, context specific signaling cascade status, as well epistatic regulation, leads to 
a complex yet interconnected target profile that varies between cell types[119]. Gli3 is processed 
as a truncated protein and functions as a transcriptional repressor of Gli genes. Gli3 has not been 
identified in OSCC with oncogenic potential, but may serve in the capacity of a tumor 
suppressor[120]. More recently, important roles for Gli3 signaling has been identified in early 
development, especially in the context of tissue polarization[121].     
Oncogenic Gli in OSCC. In OSCC, there are very few published reports investigating Hh/Gli 
signaling. Hh/Gli signaling is a known oncogene in several tumor types, especially as a driver 
mutation in basal cell carcinoma[122]. In many other tumors, such as breast, prostate, lung, brain, 
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pancreatic and colon cancer, Hh/Gli signaling serves as an important oncogenic signaling pathway 
and can promote tumorigenesis[123-127]. Specifically, in OSCC, two independent studies have 
found that Hh signaling factors serves as a prognostic indicator as Ptch and Gli correlate with 
lymphatic metastasis, tumor reoccurrence and poor prognoses[74, 98]. Molecularly, Hh/Gli 
signaling in OSCC is known to be involved in invasion and EMT, though specific signaling 
mechanisms are not reported. In terms of OSCC invasion into bone, one group demonstrated that 
Hh/Gli signaling from tumor cells can directly influence osteoblast signaling in vitro, suggesting 
that early on, tumor in bone establishment may depend on osteoblastic specific signaling 
mechanisms[128]. 
PTHrP gene structure. Hh/Gli signaling is also essential in OSCC in the context of bone 
resorption, as Gli2 is known to be involved in controlling PTHrP expression. Transcriptional 
regulation of PTHrP has been studied extensively since its discovery, but has not been investigated 
recently. The PTHrP gene contains three distinct promoters and nine exons, leading to 15 possible 
mRNA transcripts. It is not known whether Gli protein directly binds to the PTHrP promoter, but 
there are several Gli binding sites upstream of the transcriptional start site of the second promoter. 
PTHrP gene regulation. A seminal review published in 2010 discussed the known regulators of 
PTHrP[129]. Ets was the first transcriptional activator of PTHrP to be discovered, which regulates 
heavily in the P3 promoter and functions cooperatively with SP-1. Additional work done by 
Dittmer’s group also identified Smads as an important binding partner of Ets in the P3 promoter.  
Lastly, ras/MapK signaling is also known to directly regulate PTHrP expression, though this 
regulation is most often observed in squamous cell carcinomas which suggests tissue specific 
regulation of PTHrP. Binding partners important for ras/MapK mediated PTHrP expression are 
not known. In fact, mutations in Sp-1, and Smad binding sites do not prevent ras/MapK induction 
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of PTHrP expression. These findings strongly suggest that other signaling pathways must be active 
to facilitate an increase in PTHrP, which highlights Gli as a possible regulator. In OSCC, we have 
several lines of evidence that support direct regulation of Gli2 on PTHrP transcription. OSCC 
require Gli2 to increase PTHrP promoter activity and mRNA expression and we have shown that 
this involves both Smad2/3 and p38/MapK. However, promoter mapping and promoter mutation 
experiments would need to be done to definitively prove this Gli2 binding to the PTHrP promoter. 
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CHAPTER II 
HEDGEHOG AND TGFβ SIGNALING CONVERGE ON GLI2 TO CONTROL BONY 
INVASION AND BONE DESTRUCTION IN OSCC 
Introduction 
Oral Squamous Cell Carcinoma (OSCC) is a subset of head and neck squamous cell carcinomas 
(HNSCC), and accounts for the majority of cases[2, 9]. Known risk factors include smoking, 
alcohol, and chewing tobacco use[4]. Tumor resection remains the primary treatment for OSCC, 
although neoadjuvant and adjuvant therapies are often used[130]. These include radiation therapy, 
chemotherapy, neck dissection to remove lymph node metastases, and most recently, the EGFR 
inhibitory antibody, Cetuximab[28, 131]. These invasive tumors infiltrate cervical lymph nodes 
and the mandible, which is significantly correlated with increased local recurrence and decreased 
overall survival[32]. Tumors that invade into the mandible disrupt normal bone remodeling, and 
cause large amounts of bone destruction, chronic pain, and impairs eating and speaking abilities. 
These patients require surgical resection of the tumor-laden bone, which includes mandible 
reconstruction, followed by radiation therapy and other adjuvant treatments, including 
chemotherapy[132]. Unfortunately, OSCC patients have a 30-40% local recurrence rate, which 
leads to significantly reduced survival rates[33]. 
A syngeneic model of oral cancer demonstrated that PTHrP is required for OSCC invasion into 
the mandible[81]. PTHrP, a known regulator of tumor-induced bone disease, is expressed at low 
levels in healthy adult tissues, and thus it is a potential target for drug treatment[60, 133]. 
Unfortunately, the molecular mechanisms that control PTHrP expression in OSCC are not known. 
In long bone formation, PTHrP is regulated by canonical Hedgehog (Hh) signaling, where receptor 
proteins, Smoothened (Smo) and Patched (Ptch) control Gli protein and downstream target genes. 
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However, in the context of cancer, Gli can also be regulated by non-canonical Hh signaling[99], 
through direct Gli activation stemming from AKT, MEK, or S6K1 activity[134, 135]. 
Additionally, Gli can be regulated transcriptionally through other signaling pathways, where TGFβ 
and Wnt signaling can increase expression and induce activation of Gli2 independent of its 
upstream regulators[100, 136]. In OSCC, PTHrP expression can be stimulated by activation of 
Gli2 using TGFβ and our clinical data shows that Gli2 expression correlates with bony invasion. 
Here, we demonstrate that PTHrP expression is regulated by Gli2 and both Gli2 activity and PTHrP 
expression are controlled concomitantly through Hh and TGFβ signaling. Using an orthotopic in 
vivo model, we validate that bony invasion and bone destruction are regulated by PTHrP through 
modulation of Gli activity.  
Results 
PTHrP mRNA levels predict bony invasion and bone destruction in vivo. OSCC commonly 
invades with an erosive or infiltrative pattern. To discern between soft tissue invasion potential 
and bony invasion potential we utilized a well-established model of bone destruction, where tumor 
cells are inoculated directly into the tibia and allowed to establish for four weeks. Mice are then 
sacrificed and tumor burden and trabecular bone loss quantified. Using this model, we injected 
three human OSCC cell lines (SCC4, CAL27, and HSC3) and found that SCC4 cells showed 
minimal bone destruction. In contrast, CAL27 and HSC3 cells showed significantly more bone 
destruction (Figure 3A) while tumor burden remained similar to SCC4 cells (Figure 4A & 4B). To 
identify differences between OSCC cells capable of inducing destruction of mandibular bone 
compared to those that are incapable, we utilized a genome-wide microarray comparing SCC4 and 
CAL27 cells (Figure 3B and Table 1-2) to identify genes associated with bone destruction. SCC4 
and CAL27 cells were derived from Caucasian males, who have the highest incidence of OSCC 
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in the United States[2]. Additionally, the site of origin for both cell lines were the tongue, 
correlating well with the finding that a considerable number of patients with OSCC of the tongue 
develop mandibular invasion[19]. Our micro-array analyses identified genes over-expressed in the 
CAL27 cells compared to the SCC4 cells, with several genes being involved in calcium signaling. 
Of notable interest was Parathyroid Hormone-related Protein (PTHrP) which showed 30-fold 
higher expression in bony invasive CAL27 cells (Figure 3C). PTHrP and Gli2 expression levels in 
CAL27 and SCC4 cells were verified using qRT-PCR along with eight additional OSCC cell lines. 
Nine of the ten cell lines tested expressed Gli2 and PTHrP (Figure 5A & 5B). To verify these 
differences in vivo, we used immunohistochemical staining to measure PTHrP and found that 
PTHrP secretion significantly correlated with the bony invasive HSC3 cells, while SCC4-injected 
tibiae showed very little PTHrP secretion (Figure 3D and Figure 6). In addition to bone destruction, 
PTHrP levels can also predict bony invasion[90]. To verify this correlation in vivo, we used an 
orthotopic model of bony invasion, where tumor cells are injected into the masseter muscle 
adjacent to the mandible and directly invade into the surrounding tissues. SCC4 cells have minimal 
destructive effect on mandibular bone, while CAL27 cells induce significant amounts of bone loss 
(Figure 3E). These findings correlate OSCC PTHrP levels with bony invasion and bone destruction 
in two separate models. 
OSCC express PTHrP in a Gli2-dependent manner. We evaluated the contribution of Gli2 to 
regulation of PTHrP expression in OSCC using Gli Antagonist 58 (GANT58), a small molecule 
inhibitor specific to Gli[137]. Gli2 inhibition significantly decreased PTHrP expression at both 
basal and stimulated levels in several OSCC lines (Figure 7A–7C). Additionally, Gli2 is sufficient 
to increase PTHrP expression, as Gli2-SA662 overexpression induced by plasmids significantly 
increased PTHrP expression (Figure 7D & 7E) [138]. We observed that wild-type over-expression 
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Gli plasmids does not lead to increased PTHrP promoter activity (Figure 8A), but because Gli2 
expression is undetectable in many adult tissue compartments (except for basal/ stem cell 
compartments), we surmise that cells with Gli2 activity have reactivated normally silenced 
signaling mechanisms, highlighting its potential importance in OSCC tumorigenesis[75]. To 
determine if Gli2 is required for PTHrP expression, we used shRNA to stably knock-down Gli2 
expression. Loss of Gli2 prevented stimulated PTHrP expression (Figure 7F) but did not affect cell 
viability (Appendix A). Together, our findings suggest that Gli2 modulates PTHrP and is required 
for its expression. 
Figure 3. PTHrP mRNA levels predict bony invasion and bone destruction in two mouse models.  
(A) Tumor model of bone destruction. X-ray data of SCC4 cells injected into the tibiae of athymic mice show 
significantly less bone destruction than HSC3 and CAL27 cells. (B) H&E stained histological sections of SCC4 
and CAL27 tumors taken from tip-of-the-tongue injections in athymic mice show morphological differences. SCC4 
cells bear an erosive phenotype, while CAL27 cells bear an infiltrative phenotype. (C) PTHrP is upregulated almost 
30-fold in bony invasive OSCC. The top ten upregulated genes as determined from a genome wide microarray study 
comparing mRNA levels of CAL27 cells (bony invasive OSCC) vs SCC4 (non-bony OSCC). PTHrP is highlighted 
because it is known to be essential for OSCC bony invasion. (D) PTHrP levels correlate with bony invasion status. 
SCC4 cells injected into the tibiae of athymic mice show low PTHrP staining by IHC, while HSC3 cells show 
significantly larger amounts of PTHrP expression, as denoted by the black arrows. (Images at 40X, scale bar is 
200μm) (E) Orthotopic model of bony invasion. Representative μCT scans of mandibles dissected from mice 
bearing tumors from masseter muscle injections. SCC4 cells show minimal bone destruction and small amounts 
of new bone formation, while CAL27 cells show extensive bone destruction. 
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Table 1. HSC3 microarray data  
 
Table 1. HSC3 microarray data  
mRNA expression of the indicated genes is shown via heat map, where gray represents no change in gene expression 
compar d to control. Light blue and dark blue indicate downregulation in the two and four-fold range respectively, while 
orange and red indicate upregulation in the two and four-fold range, respectively. 
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Table 2. SCC4 microarray data  
mRNA expression of the indicated genes is shown via heat map, where gray represents no change in gene expression 
compared to control. Light blue and dark blue indicate downregulation in the two and four-fold range respectively, while 
orange and red indicate upregulation in the two and four-fold range, respectively. 
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Figure 4. SCC4 and HSC3 tumor burden is not significantly different in vivo 
(A) SCC4 and HSC3 tumors have comparable tumor area. SCC4 and HSC3 tumors cells injected into the tibia have 
tumor areas that are not statistically significant by histological analyses. (B) Representative images of SCC4 and HSC3 
tumor bearing tibias show similar tumor burden. 4X and 20X representative images of H&E stained tibia sections show 
similar tumor burden.  
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Figure 5. Gli2 and PTHrP is expressed by nine of ten OSCC cell lines tested. (A) OSCC express varying levels of Gli2. 
By qRT-PCR, all OSCC cell lines tested, except SCC9, expressed 
Gli2 mRNA at differing levels when kept in serum free conditions for 24 hours. (B) OSCC express varying levels of 
PTHrP. By qRT-PCR, all OSCC cell lines tested, except VU-SCC1729, expressed PTHrP mRNA at differing levels when 
kept in serum free conditions for 24 hours. 
 
A. 
B. 
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Figure 6. Bony invasive status correlates with PTHrP levels in vivo. The bony invasive OSC cell line HSC3 express 
significantly more PTHrP protein than the non-bony invasive SCC4 OSCC cell line. Representative images (4X and 20X) 
of SCC4 or HSC3 cells injected into the tibia demonstrate different levels of PTHrP protein as shown by IHC staining. 
Black dotted lines indicate tumor front. 
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Figure 7. OSCC express PTHrP in a Gli2 dependent manner. (A-C) Gli2 inhibition decreases basal PTHrP 
expression and suppresses TGFβ induced PTHrP expression. qRT-PCR was used to determine PTHrP mRNA 
levels of three OSCC cell lines (CAL27, SCC4, and HSC3) that were treated with 10uM of the Gli inhibitor, 
GANT58 or the solvent control DMSO, with or without the addition of 10ng/ml TGFβ, which induces PTHrP 
expression. In all groups GANT58 treatment significantly decreased PTHrP expression. (D & E) Gli2 over-
expression significantly increases PTHrP expression. SCC4 and CAL27 cells were co-transfected to overexpress 
Gli2 SA662 Flag (Gli2 protein resistant to ubiquitination based proteosomal degradation), as well as a PTHrP 
firefly luciferase reporter plasmid and a constitutively active Renilla luciferase reporter plasmid. 48 hours later 
cells were harvested and firefly activity quantified. In both lines, Gli2 over-expression increased PTHrP. (F)  
shRNA mediated Gli2 silencing prevents TGFβ induced PTHrP expression. qRT-PCR was used to determine 
PTHrP mRNA levels in CAL27 cells transfected with non-coding hairpins or a pool of four independent hairpins 
against Gli2. Both groups showed low basal expression of PTHrP, but when treated with TGFβ, control cells 
significantly increased PTHrP mRNA expression while Gli2 deficient cells were unable to increase PTHrP mRNA. 
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Hedgehog receptor signaling is required for Gli2 activity and PTHrP expression. As the 
canonical regulator of Gli2, we examined the role of receptor based Hh signaling on regulating 
Gli2 activity and PTHrP expression using purmorphamine, a Smo-specific agonist, or 
cyclopamine, a Smo-specific antagonist. We demonstrate that purmorphamine significantly 
increased Gli2 promoter activity (Figure 9A & 9B) as well as Gli2 protein activity using luciferase-
based reporter assays (Figure 9C). As expected, cyclopamine significantly decreased stimulated 
Gli2 expression (Figure 9D) and prevented an increase of stimulated levels of PTHrP, highlighting  
the requirement of canonical Hh signaling for PTHrP expression (Figure 9E). Unexpectedly, 
purmorphamine did not significantly increase PTHrP expression (Figure 9F & 9G) and activation 
of Smo using Indian hedgehog protein (Ihh) showed similar results (Figure 8B). To determine if 
Hh signaling was being silenced by proteasome mediated Gli degradation, we used bortezomib, a 
Canonical Hh activation does not increase PTHrP expression levels 
Figure 8. (A) Gli protein overexpression does not increase PTHrP promoter activity. SCC4 cells transfected to overexpress 
Gli protein do not increase PTHrP promoter activity after 24 hours as shown by DLR assay. (B) Exogenous Hh ligand does 
not increase PTHrP mRNA expression. SCC4 cells treated with Ihh ligand or purmorphamine do not increase PTHrP 
mRNA expression after 24 hours of treatment. 
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proteasome inhibitor, and measured PTHrP expression. While bortezomib treatment doubled 
PTHrP levels in cells treated with PURMO, this increase was quite negligible as compared to 
TGFβ. To investigate this further, we stimulated cells with either TGFβ or PURMO, and then 
treated them with Actinomyosin D (to prevent transcription) for different time periods. This was 
done to investigate whether these treatments affected PTHrP mRNA stability. We observed that 
canonical Hh signaling potently, but very transiently, increases PTHrP expression (Appendix B). 
Collectively, these observations suggest that Hh signaling is necessary but not sufficient for PTHrP 
expression, and thus other pathways are required. 
Figure 9. Hedgehog receptor signaling is required for Gli2 activity and PTHrP expression but alone is not 
sufficient for PTHrP expression. (A & B) Hh stimulation increases Gli2 promoter activity. OSCC cells were 
transfected using luciferase based reporter plasmids to assay endogenous Gli2 promoter activity and then stimulated 
with 10uM purmorphamine, resulting in a significant increase in Gli2 promoter activity. (C) Hh stimulation increases 
Gli protein activity. OSCC cells were transfected using luciferase based reporter plasmids to assay Gli2 protein 
activity, and then stimulated with purmorphamine, resulting in a significant increase in Gli2 protein activity. (D & E) 
Canonical Hh signaling is required for both Gli2 and PTHrP expression. qRT-PCR was used to determine PTHrP 
mRNA levels of CAL27 cells that were treated with 12nM of cyclopamine, or the solvent control DMSO, with or 
without the addition of TGFβ. Cyclopamine decreased basal PTHrP expression as well as significantly inhibited TGFβ-
induced PTHrP expression. Inset demonstrates the dual role of Gli2 protein to increasing Gli2 and PTHrP expression. 
(F & G) Hh stimulation is not sufficient to increase PTHrP expression. qRT-PCR was used to determine PTHrP 
mRNA levels of CAL27 cells that were treated with purmorphamine, which did not induce PTHrP expression, but 
instead decreased basal levels of PTHrP, suggesting a possible feedback loop. 
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TGFβ signaling modulates Gli2 and PTHrP expression. Studies on breast cancer metastasis to 
bone highlight the importance of PTHrP for regulation of bone destruction by a non-canonical 
Gli2-dependent mechanism through TGFβ signaling[66, 67]. Several lines of evidence support 
TGFβ signaling induction of Gli independent of Hh signaling[100, 139, 140]. We examined the 
role of TGFβ on regulating Gli2 and PTHrP and found that TGFβ stimulation significantly 
increased levels of PTHrP expression (Figure 10A & 10B). Moreover, increased PTHrP expression 
is facilitated through canonical TGFβ signaling, since the use of Smad protein over-expression 
plasmids led to a marked increase in PTHrP expression (Figure 10C). Inhibition of canonical TGFβ 
signaling using the Smad3 inhibitor, SIS3, decreased PTHrP expression (but not significantly), 
and inhibition of non-canonical TGFβ signaling using the p38/MAPK inhibitor, SB202190, 
significantly decreased Gli activity and PTHrP expression (Figure 10D & 10E). Importantly, the 
TGFβ mediated increased of PTHrP expression correlates with an increase in both Gli2 promoter 
and protein activity levels (Figure 10F & 10G). 
Intracellular Wnt signaling increases PTHrP expression through crosstalk with Hh signaling. 
Wnt signaling plays an essential role in bone biology, and research has demonstrated its 
significance in supporting metastases to bone[64, 141]. We explored the role of Wnt signaling in 
OSCC to increasing PTHrP expression using Lithium Chloride (LiCl) to inhibit activity of 
glycogen synthase kinase-3β (GSK-3), a negative regulator of Wnt signaling. Wnt activation was 
found to have no effect on PTHrP expression (Figure 11A & 11B). Additionally, qRT-PCR for the 
Wnt target gene, DKK1, showed no significant changes in expression between control and LiCl-
stimulated cells (Figure 11C), suggesting that canonical Wnt signaling is inactive. Since Wnt 
signaling may play a role in PTHrP expression downstream of GSK-3, we evaluated the role of β-
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catenin, the downstream effector protein, on PTHrP expression. We found that β-catenin over-
expressing plasmids increased PTHrP expression levels. 
 
 
Figure 10. TGFβ signaling modulates Gli2 and PTHrP expression. (A & B) TGFβ signaling increased PTHrP 
expression. qRT- PCR was used to determine PTHrP mRNA levels of SCC4 and CAL27 cells that were treated 
with TGFβ or the buffer control. TGFβ treatment significantly increased PTHrP in all cell lines tested. (C) 
Smad2/3 over-expression increased PTHrP expression. SCC4 cells were co-transfected to overexpress equal 
amounts of Smad2 and Smad3 (see insert for protein confirmation by Western blot), as well as a PTHrP firefly 
luciferase reporter plasmid and a constitutively active Renilla luciferase reporter plasmid. 48 hours after 
transfections, cells were harvested and firefly activity quantified. Smad over-expression significantly increased 
PTHrP promoter expression. (D & E) Canonical and non-canonical TGFβ inhibition decreased Gli activity and 
PTHrP expression. qRT-PCR was used to determine PTHrP mRNA levels of SCC4 cells treated with TGFβ, and 
SIS3, a Smad3 inhibitor, or SB202190, a p38/MAPK inhibitor. While Smad3 inhibition trended to significantly 
decrease Gli activity and PTHrP expression, only p38/MAPK inhibition significantly decreased both. (F & G) 
TGFβ signaling increased Gli2 promotor and protein activity. SCC4 cells were co-transfected with an endogenous 
Gli2 promoter construct, or a Gli2 protein reporter construct, as well as a constitutively active Renilla luciferase 
reporter plasmid. 24 hours after transfections, cells were treated with TGFβ or the buffer control and harvested 24 
hours later before firefly activity was quantified. Both promoter and protein activity of Gli2 was significantly 
increased with TGFβ signaling. Inset demonstrates the dual role TGFβ signaling has on increasing Gli2 at the 
level of mRNA as well as protein. 
 
PTHrP levels decrease when two β-catenin inhibitory proteins, dominant negative TCF4 and 
ICAT, are over-expressed (Figure 11D). There are several β-catenin/TCF4 binding sites on the 
promoter region of Gli2[142], so we tested the role of β-catenin to increasing Gli2 promoter 
 34 
activity using luciferase-based reporter assays and found that β-catenin significantly increased 
Gli2 promoter activity (Figure 11E). We tested the requirement of intracellular Wnt signaling for 
PTHrP expression using the small molecule Wnt inhibitor VUWS113, which led to a significant 
reduction in stimulated levels of PTHrP (Figure 11F). Surprisingly, direct inhibition of Wnt 
signaling at the receptor level using Sclerostin significantly increased PTHrP expression (Figure 
12), which highlights abnormal Wnt signaling and indicates possible downstream crosstalk with  
 
Figure 11. Intracellular Wnt signaling increases PTHrP expression through crosstalk with Hh signaling. 
(A & B) Wnt signaling activation is insufficient to increase PTHrP expression. SCC4 cells were treated with 
LiCL and PTHrP mRNA measured by qRT-PCR. Li Cl treatment does not significantly increase PTHrP 
expression. Similar results were seen for PTHrP promoter activity by dual-luciferase assays in CAL27 cells treated 
with LiCl for 24hours. (C.) Canonical Wnt signaling is not active in OSCC. CAL27 cells were treated with Li-Cl, 
TFGβ, or control for 24 hours before being harvested for qRT-PCR. Active Wnt signaling, indicated by higher 
levels of the β-catenin target gene DKK1, is observed with TFGβ but not Li-Cl stimulation. (D) Intracellular 
Wnt signaling modulates PTHrP expression. SCC4 cells were transfected to express a PTHrP firefly luciferase 
reporter and a constitutively active Renilla luciferase reporter plasmid in combination with a β-catenin protein 
expressing plasmid, a dominant negative TCF4 protein expressing plasmid, or an ICAT protein expressing 
plasmid. Intracellular Wnt activation using β-catenin led to a significant increase in PTHrP promoter activity; 
while inhibitors of β-catenin decreased PTHrP promoter activity. (E) β-catenin over-expression increases Gli2 
promoter activity. SCC4 cells were transfected to express an endogenous Gli2 promoter firefly luciferase reporter 
and a constitutively active Renilla luciferase reporter plasmid in combination with a β-catenin protein expressing 
plasmid. 48 hours after transfection, cells were harvested and firefly activity quantified, which demonstrated a 
significant increase in Gli2 promoter activity, quite similar to that of PTHrP promoter activity. (F) Intracellular 
Wnt inhibition decreases PTHrP expression. qRT-PCR was used to determine PTHrP mRNA levels of CAL27 
cells that were treated with or without 10uM of the CK1 inhibitor, VU-WS113. Treatment with VU-WS113 
significantly decreased PTHrP expression. 
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Gli. Indeed, indirect modulation of Wnt signaling using LiCl and VU-WS113 have been shown 
to affect Hh signaling as reported[143]. Together, our data support that Wnt signaling in OSCC 
is irregular; suggesting that only Wnt activation at the level of β-catenin consistently modulates 
PTHrP expression, where Gli2 expression is also increased. 
 
Figure 12. Wnt signaling is dysregulated in OSCC and cross-talks with Hh/Gli signaling. (A) Sclerostin 
treatment increase PTHrP expression. SCC4 cells treated with Sclerostin to inhibit Wnt signaling at the 
receptor level show increased levels of PTHrP mRNA after 24 hours of treatment, similar to TGFβ 
stimulation. (B) CK1 inhibition decreases Gli activity. SCC4 cells treated with the small molecule Wnt 
inhibitor (VU-WS113) show decreased levels of PTHrP mRNA after 24 hours of treatment. 
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Gli2 expression is required to increase PTHrP expression, bony invasion and bone destruction. 
To validate that Gli2 is required for bony invasion, we utilized shRNA to stably knock down 
expression of Gli2 in bony invasive CAL27 cells (Figure 13A). Non-silencing control cells and 
shGli2 cells were injected into the masseter muscle of male athymic mice and allowed to progress 
for eight weeks. While both groups developed tumors, control tumors had significantly increased 
levels of bony invasion as well as bone destruction (Figure 14A). Surprisingly, loss of Gli2 led to 
smaller tumors, some of which were unable to invade into surrounding tissues. CAL27 shGli2 
tumors had significantly lower PTHrP protein levels as determined by IHC (Figure 14B images) 
and histological data confirmed loss of Gli2 protein in the tumors (Figure 13A images). 
Additionally, Tartrate Resistant Acid Phosphatase (TRAP staining) confirmed a significantly 
smaller number of osteoclasts at the tumor-bone interface in mandibular sections (Figure 14C). 
Gli2 levels correlate with bony invasion in clinical OSCC samples. OSCC samples from patients 
were characterized as bony invasive if patients underwent a mandibulectomy or non-bony invasive 
if patients only underwent soft tissue surgery. Eight samples of both bony invasion and non-bony 
invasion were used to measure Gli2 mRNA expression levels. By qRT-PCR, patients with bony 
invasion had significantly higher expression of Gli2 (Figure 14D). Additionally, immuno-
histochemical staining of a larger cohort of paraffin embedded OSCC samples showed similar 
results for Gli2 protein, where Gli2 levels were significantly up-regulated in bony invasive samples 
(Figure 14E). These findings are clinically relevant, as Gli2 and TGFβ1 are significantly co-
expressed in a cohort of 279 head and neck carcinomas catalogued in cBioPortal (Figure 
13B)[144].  
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Co-occurrence of Gene A and Gene B in 279 HNSCC samples (Modified from cBioPortal) 
Gene A Gene B p-value 
Gli2 TGFβ 0.043 
Figure 13. Gli2 knock-down tumors remain Gli2 negative in vivo and Gli2 and TGFβ significantly co-occur in HNSCC 
patients. (A) shRNA against Gli2 significantly decrease Gli2 expression in OSCC. CAL27 cells transfected to stably express 
shRNA against Gli2 show significantly reduced levels of Gli2 mRNA by qRT-PCR. Representative images of CAL27 tumors show 
active Gli2 protein in control transfected cells and very little Gli2 protein in shGli2 transfected cells. (Positive staining is denoted 
by black arrows) (B.) Gli2 and TGFβ significantly co-occur in HNSCC patients. Using the cBioPortal resource, a significant 
correlation was found between Gli2 and TGFβ1 expression in a cohort of 279 patients with head and neck cancer. 
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Figure 14. Gli2 is required to increase PTHrP expression, bony invasion and bone destruction. (A) Loss of Gli2 
using shRNA decreases bone destruction in vivo. CAL27 cells stably expressing shRNA against a non-silencing 
control sequence or Gli2 were injected into the masseter muscle of male athymic mice and allowed to progress for 
eight weeks. Mice were then sacrificed and mandibles dissected for high resolution x-rays. Significantly less bone 
destruction, as measured by lesion area, was observed in the shGli2 group. (B) Loss of Gli2 decreases PTHrP levels 
in vivo. CAL27 tumors expressing shRNA against Gli2 show significantly lower PTHrP protein levels by IHC. (Inset 
is 40X with 200μm scale bars. Arrows denote positive staining) Loss of Gli2 expression is verified using IHC. (C) 
Loss of Gli2 decreases osteoclasts numbers in vivo. Tartrate Resistant Acid Phosphate (TRAP) staining was used to 
identify osteoclasts at the tumor bone interface of mandible sections. We found a significantly larger number of 
TRAP-positive multinucleated cells in the control group as compared to the shGli2 group. (D) Gli2 mRNA is 
associated with bony invasion in clinical samples. qRT-PCR was done on human OSCC clinical samples, where 
patients that underwent a mandibulectomy were classified as bony invasive (BI), while samples from patients who 
did not undergo a mandibulectomy were classified as non-bony invasive (NBI). Samples from the BI group had 
significantly higher expression of Gli2. (E) Gli2 protein correlates with bony invasion in human clinical samples. A 
larger cohort of clinical samples based on the selection criteria described above was used for IHC against Gli2. We 
show that Gli2 protein also significantly correlated with bony invasion. 
 
Discussion 
We have demonstrated that in OSCC, Gli2 is the central regulator of PTHrP expression (Figure 
15). Importantly, we have identified several signaling pathways that control Gli2 at the level of 
mRNA expression and protein activity. Gli2 directly correlates with PTHrP expression and is both 
necessary and sufficient for PTHrP expression. Along with Hh signaling, we have identified TGFβ 
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signaling as a major contributor to Gli activation and we show that both pathways are important 
for increasing Gli levels and thus PTHrP expression. We have also identified Wnt signaling as an 
activating pathway for Gli, although this seems to be driven in a non-canonical manner. Targeting 
Gli2 in OSCC using shRNA significantly decreased PTHrP expression and prevented bony 
invasion and bone destruction in vivo. Finally, our clinical data showing that Gli2 levels correlate 
with bony invasion strongly supports our findings that Gli2 controls PTHrP expression in OSCC. 
Canonical Hh signaling is a highly conserved signaling pathway essential for normal development 
in higher organisms. In adults, Hh signaling is silenced in almost all tissues, but is often reactivated 
in tumorigenesis. Basal cell carcinoma and medulloblastoma are Hh-driven tumors, where loss of 
Ptch leads to constitutive activation of Hh signaling[145]. Additionally, there are reports of 
canonical and non-canonical Hh signaling in other tumor types, such as breast, lung, prostate, and 
colon, where Hh signaling is not the driving mutation but is involved in tumor progression and 
contributes to treatment failure and tumor recurrence[99, 126]. There have also been several 
published findings on Hh signaling in OSCC, where it is known that Hh signaling contributes to 
growth, migration and invasion[98, 146]. In our system, OSCC signals through both canonical and 
non-canonical Hh signaling to increase Gli2 activation and expression of downstream target genes. 
Alternatively, both TFGβ and Wnt signaling pathways activate transcription of Gli2, and we show 
that TFGβ increases Gli2 protein activity as well. Our findings highlight the complexity of Gli 
regulation and PTHrP expression in OSCC and demonstrate the importance of inhibiting Hh 
signaling at the level of Gli, as compared to upstream receptor-based inhibition.  
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Figure 15. Proposed Mechanism of Gli2 Mediated Bone Destruction in OSCC.  
OSCC signals through several signaling pathways to increase Gli2 and PTHrP. Canonical Hh signaling activates 
Gli2 protein accumulation and increases Gli2 expression, both of which can increase PTHrP expression. TGFβ 
signaling increases Smad2/3 activation, which increases Gli2 expression. Increased p38/MAPK activity can also 
increase Gli2 levels by stabilizing Gli2 protein. B-catenin activation increases Gli2 expression and directly and may 
also indirectly affect Gli2 protein levels through cross-talk. Gli2 increases PTHrP expression in OSC, which results 
in an increase in osteoblast-mediated osteoclast activation, resulting in large amounts of bone resorption.  
 
The contribution of Wnt signaling to Gli2 and PTHrP activation is also complex. While Wnt 
signaling in OSCC does not appear to be normal, β-catenin activation can modulate PTHrP 
expression, and this activation occurs via Gli2. The inability of cells to respond to Wnt stimulation 
led us to believe that Wnt signaling was not active in these cells, thus, we found it surprising that 
Wnt inhibition could decrease PTHrP expression. We investigated if this inhibition was 
independent of Gli2 using qRT-PCR and found that VU-WS113 treatment significantly decreased 
Gli2 protein activity (Figure 12B), supporting the concept of crosstalk between the two pathways. 
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Indeed, the mechanism of Wnt inhibition using VU-WS113 is through inhibition of CK1, an 
inhibitory kinase of β-catenin that has been shown to be a potent inhibitor of Hh signaling[143]. 
These findings are in line with reports of crosstalk between canonical Hh and Wnt signaling, which 
has been documented in normal development, wound repair and tumorigenesis[136, 147, 148]. 
Additionally, inhibition of Wnt signaling at the receptor level using Sclerostin increased PTHrP 
expression, suggesting that while β-catenin activation increases Gli2 and PTHrP expression, 
upstream activation of Wnt signaling has an opposite effect. These results are consistent with other 
literature showing that Hh and Wnt signaling can function as negative regulators of one 
another[149]. Thus, our data strongly suggests that Wnt regulation of PTHrP occurs at least in part, 
via Gli2. In several OSCC lines tested, TGFβ stimulation led to an increase in PTHrP expression, 
with a similar increase in Gli2 transcription and protein activity. This was found to be mediated in 
a Smad-dependent manner. As there are several published reports demonstrating that the Smad 
binding sites on the Gli2 promoter are functional, we surmise that Gli2 is a direct target of TGFβ 
signaling. The contribution of non-canonical TGFβ signaling on increasing Gli2 and PTHrP 
expression is also in line with other published findings, where several downstream targets of 
p38/MAPK including MEF2C and NF-kβ can induce expression of Hh ligands as well as Gli[99]. 
Our group has published on TGFβ mediated activation of Gli2 in other tumor types that do not 
express the conical Hh signaling receptors, Smo and Ptch. We have found however, that in OSCC, 
canonical Hh signaling is required for TGFβ stimulation to increase Gli activity and PTHrP 
expression, suggesting a cooperative or synergistic signaling system. Taken together, our data 
demonstrates a complex yet interconnected signaling network controlling PTHrP expression. 
Importantly, these mechanisms all converge on Gli2, highlighting its importance on regulating 
PTHrP expression. Previous findings have highlighted the importance of PTHrP for bony invasion 
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in murine OSCC, but until now, the mechanism controlling PTHrP expression remained 
unknown[81]. Other studies have shown the prognostic value of PTHrP expression for predicting 
bony invasion using human samples, and we have built upon these findings to both identify and 
test regulators of PTHrP. It is important to note that Gli2 regulation of PTHrP is observed in other 
tumors. In tumors that metastasize to bone, PTHrP plays an important role in promoting tumor 
progression and bone destruction[67]. In a process coined “The Vicious Cycle”, metastatic tumor 
cells arrive at the bone microenvironment and secrete factors that directly or indirectly lead to 
excessive osteoclast-mediated bone resorption. In bone-metastatic MDA-MB-231 breast cancer 
cells, PTHrP expression has been shown to be regulated by non-canonical Hh signaling[66]. 
Similar to OSCC, these cells increase Gli2 levels in response to TGFβ, which leads to an increase 
in PTHrP. Dissimilar to OSCC however; PTHrP in breast cancer cells can also be modulated by 
classical Wnt signaling. Additionally, bone metastatic MDA-MB-231 cells do not express 
canonical Hh receptor signaling proteins, nor do they respond to Hh receptor based inhibition or 
activation, highlighting the complexity of PTHrP and Gli2 regulation in different systems[66]. 
OSCC invasion into the mandible is a serious occurrence that significantly impacts patient overall 
survival and quality of life. These patients have high rates of recurrence at or near the site of the 
original tumor, emphasizing the need for more effective anti-tumor therapies. Currently, the only 
FDA approved targeted treatment for OSCC is Cetuximab, a monoclonal antibody against EGFR. 
While Cetuximab significantly increases overall survival in patients with locally advanced disease, 
patients with recurrent and/or metastatic disease only survive three months longer when 
Cetuximab is added to their treatment regimen. Thus, it is clear that other targets are needed. 
PTHrP expression significantly correlates with bone involvement in OSCC patient samples and 
previous studies have identified PTHrP as an essential component of bony invasion and bone 
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destruction in OSCC. However, no published work on PTHrP regulation in OSCC exists. Through 
this study, we have identified key signaling mechanisms that control PTHrP-mediated bony 
invasion. The contributions of Hh, TGFβ, and Wnt signaling on Gli2 strongly suggest that bony 
invasion is regulated in a multifaceted system. The variability of receptor signaling control among 
OSCC cell lines highlights the importance of targeting the common downstream mediator, Gli2. 
Our work highlights mechanisms that can contribute to the observed clinical failures of Smo 
inhibitors, and we have demonstrated the value of targeted downstream Gli inhibitors to prevent 
treatment resistance and disease recurrence[150]. We have provided sufficient evidence to support 
that Gli2 controls bony invasion and bone destruction in OSCC via regulation of PTHrP. Our 
findings highlight the feasibility of using Gli2 inhibitors to prevent mandibular invasion and bone 
destruction in OSCC patients and should be evaluated further as a possible adjuvant treatment. 
 
Materials and Methods 
Cell lines  
The OSCC cell lines, SCC4, CAL27, and HSC3 were provided by Cara Gonzales at UTHSCSA, 
and were purchased from American Type Culture Collection (ATCC). The remaining OSCC cell 
lines, SCC9, SCC15, SCC25, SCC61, SCC131, SCC1352, and VU1729 were donated by Dr. 
Stephen Brant at Vanderbilt University. Cell lines were tested for mycoplasma and if positive, 
were treated with BM Cyclin (Roche). Cell lines were cultured in 50% Dulbecco’s modification 
of Eagle’s medium and 50% Nutrient Mixture F12 (DMEM/F12) (ThermoFisher Scientific), 
supplemented with 10% fetal bovine serum (FBS) (Hyclone Laboratories) and 1% penicillin/ 
streptomycin (Mediatech). Cells were maintained at 37°C with 5% CO2.  
Genome wide microarray  
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Total RNA was extracted from OSCC cells stimulated with TGFβ or the buffer control using RNA 
Stat 60 reagent (AMSBIO) according to the manufacturer’s protocol. The RNA was sent to the 
UTHSCSA Microarray  
Core facility and used as a template for double-stranded cDNA synthesis, followed by biotin-
labeled cRNA synthesis. The cRNA was fragmented and hybridized to the U133A GeneChips 
overnight at 45°C in a rotating incubator. Hybridized cRNA was fluorescently labeled with anti-
biotin antibodies and streptavidin phycoerythrin dye conjugate on a programmable microfluidics 
workstation. The probe arrays were scanned twice and the stored images were analyzed using the 
GeneChip MAS 5.0. Signal intensities were normalized and scaled using MAS 5.0 for comparison 
analysis of experimental and baseline arrays. Significantly up-regulated and downregulated genes 
were identified by MAS 5.0. 
Drug treatments  
All drug treatments were carried out in serum free DMEM/F12 for 24 hours. TGFβ and Sclerostin 
(R&D Systems) were used at 10ng/ml and 1-2ug/ml respectively. TGFβ buffer (5%BSA in 4mmol 
HCl) was used as a control. GANT58 and Lithium Chloride (SigmaAldrich) were used at 10μM 
and 20mM respectively. Purmorphamine and SIS3 (EMD Millipore) were used at 10μM. 
Cyclopamine (LC Labs) was used at 12nM. SB202190 (Tocris) was used at 10μM. VU-WS113, a 
less cytotoxic derivative of Pyrvinium, was a gift from Dr. Ethan Lee at Vanderbilt University. 
Transfections Cells were transfected per manufacturer’s instructions using Lipofectamine 2000 
(ThermoFisher Scientific). Briefly, cells were incubated overnight in OptiMem (ThermoFisher 
Scientific) before being transfected at a ratio of 1.25 ug DNA to 1ul Lipofectamine 2000. Fresh 
media (complete with FBS and antibiotics) was added to cells the following morning. Transiently 
transfected cells were harvested 48 hours after transfections, while stably transfected cells were 
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maintained in antibiotic media. 400ug/ml G418 or 125 ng/ml puromycin were used for two weeks 
to select for transfected cells. Thereafter, cells were cultured in antibiotic maintenance media, 
which was 200ug/ml G418 or 62.5 ng/ml puromycin. 
Plasmids for stable transfections  
Gli2-SA662 Flag was a gift from Vladimir Spiegelman from the University of Wisconsin Medical 
School. The Gli2 protein produced from these plasmids harbor a single point mutation, changing 
the serine at amino acid position 662 to alanine. This enables resistance to proteasomal degradation 
by ubiquitination [21]. Three pooled shRNA constructs against Gli2 and the non-silencing control 
(Origene) were used to knock-down Gli2 expression. DNA amounts between groups were held 
constant. 
Plasmids for transient transfections  
The pRL Renilla Luciferase Control Reporter plasmid (Promega) and the PTHrP promoter plasmid 
were used as described [48]. The Gli2 promoter and protein reporter plasmids, as well the β-catenin 
plasmids were also a gift from Vladimir Spiegelman. The Smad2/3 protein plasmids were a gift 
from the laboratory of Dr. Harold Moses at Vanderbilt University. 
Quantitative real-time PCR  
Cells were harvested by direct lysis and total RNA extracted using the RNeasy Mini Kit (Qiagen). 
The qScript cDNA synthesis kit (Quanta, VWR) was used to synthesize cDNA from 1ug RNA. 
Validated Taq-Man primers from (ThermoFischer Scientific) were used to measure gene 
expression in triplicate using the 7500 Real-Time PCR System from Applied BioSciences 
(ThermoFisher Scientific). Absolute gene expression was quantified using a standard curve and 
18s was used as an internal control. 
Western blots  
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Briefly, cell lysate was harvested using RIPA Buffer (Sigma) supplemented with protease and 
phosphatase inhibitors (Roche). 20ug of protein were loaded per well and gels were run using Nu 
Page supplies (Novex by Life Technologies) before being transferred to PVDF membranes. 
Membranes were blocked in TBS with .1% Tween-20 and 5% BSA or 5% non-fat dry milk for 1 
hour. Primary antibody incubations of GAPDH, Smad3 and phospo Smad3 (Cell Signaling) were 
done overnight at four degrees under gentle agitation, and the secondary antibody, anti-rabbit IgG 
(Cell Signaling) was incubated for one hour at room temperature under gentle agitation. 
Membranes were exposed on x-ray film using Western Lightening PlusECL (Perkin Elmer). 
Animal studies  
All animal studies were carried out in compliance with the Vanderbilt University Institutional 
Animal Care and Use Committee and the National Institutes of Health guidelines. Intra-tibial 
injections 5x105 cells were injected into the left tibia of 4-6-week-old athymic male mice from 
Harlan Laboratories. The right tibia was used as a PBS injection control. Weekly x-rays using the 
XR-60 digital radiography system from Faxitron were done to monitor tumor progression. At the 
end of the experiment, mice were sacrificed and hind limbs dissected for ex vivo analyses. 
Masseter muscle injections 1x106 cells were injected into the left masseter muscle (parallel to the 
mandible) of 4-6-week-old athymic male mice from Harlan Laboratories. The right muscle was 
used as an injection control. Mice were weighed weekly to assess tumor burden. Drug treatments 
began once tumors were palpable (~10 days). At the end of the experiment, mice were sacrificed 
and mandibles were dissected for ex vivo analyses. 
Clinical OSCC samples  
Dr. Kim Ely reviewed patient charts to identify OSCC patients that underwent a mandibulectomy 
as compared to those that underwent soft tissue removal, which was used to acquire 30 total OSCC 
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samples on histological slides from the Translational Pathology Shared Resource Core at 
Vanderbilt. 16 available matching macrodissections were acquired from the Vanderbilt-Baker 
Head and Neck Bio-repository, and processed for qRT-PCR as described. 
Immunohistochemical staining  
Mandible specimens were dissected and fixed in 10% neutral-buffered formalin (Fisher Scientific) 
for 48 hours at four degrees. Mandibles were then decalcified in 10% EDTA for 10 days at room 
temperature under agitation and embedded in paraffin. Mandible sections (5-7μm thickness) were 
stained with hematoxylin & eosin, orange G, and phloxine to measure tumor burden. Antibody 
staining against Gli2 (Novus Biologicals at 1:250) was used to measure Gli2 protein expression. 
Antibody staining against PTHrP (Jack Martin at 1:400) was used to measure PTHrP protein 
expression. Unlabeled goat IgG and rabbit IgG from Santa Cruz (1:400) were used as control 
primary antibodies. HRP linked rabbit anti-goat or goat anti-rabbit and ImmPACT NOVA RED 
from Vector Laboratories was used to detect staining. TRAP staining was used to measure 
osteoclast numbers. All slides were examined under an Olympus microscope at 20X and 40X and 
images (taken using Olympus DP71 camera and software) were quantified using Metamorph 
software (Molecular Devices, Inc.) for thresholding and region of interest (ROI) analysis. 
Immunohistochemical analyses  
Histological images from HRP-labeled antibody staining were uploaded into Metamorph. For each 
image, the bottom incisor was used as a landmark. The area of tumor was traced using region of 
interest analyses, then, positive staining was quantified for each slide using a representative 
threshold (based on the positive control). For PTHrP, positive staining is marked by tumor specific 
brown staining. For Gli2, positive staining is marked by tumor specific nuclear brown staining. 
Nonspecific staining from the IgG control was used measure background staining. This value was 
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subtracted from each slide to normalize values. The resulting value represents positive staining, 
which is then divided by the total area of the image yielding percent positive staining. Similarly, 
tumor burden in tibiae were assessed using H&E staining, where tumor area is quantified and 
divided by the total area (total marrow space of tibia from the growth plate to near mid-shaft). 
Statistical analyses and replicates  
All in vitro experiments were done in triplicate with a minimum n =3 samples. For intra-tibial 
injections, n=8 mice per group. For masseter muscle injections, n=10 mice per group. All statistical 
analyses were done using InStat v3.03 software from GraphPad Software. All values are presented 
as mean ± SEM where * denotes p<.05, ** denotes p<.01 and *** denotes p<.001. 
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CHAPTER III 
GLI INHIBITION, USING LOCALLY DELIVERED ENCAPSULATED GANT58, 
PREVENTS MECHANOTRANSDUCTION MEDIATED ORAL CANCER INVASION 
INTO BONE 
Introduction 
Oral Squamous Cell Carcinoma (OSCC) accounts for most Head and Neck Squamous Cell 
Carcinomas (HNSCC) and has a five-year mortality rate of 64% [2, 9]. Invasion status remains the 
most important prognostic factor for recurrence and overall survival. This is especially evident in 
patients with mandibular invasion, which predicts poor prognoses[32].  Patients with bony 
invasion require surgical resection, along with additional therapies such as radiation, 
chemotherapy, and immunotherapy[28, 130, 131]. Even so, many patients suffer from tumor 
recurrence, which significantly decreases mortality. Advancements in OSCC treatments are 
limited, in part, by a fundamental lack of knowledge concerning how and why OSCC invades into 
mandibular bone. OSCC cells that invade the bone can express factors such as Parathyroid 
Hormone-related Protein (PTHrP) and Receptor Activator of Nuclear Factor-B Ligand (RANKL), 
which indirectly and/or directly stimulate excessive osteoclast-mediated bone destruction[60, 81, 
90, 151].  While the mechanisms behind this expression in OSCC had remained unclear, our group 
recently demonstrated that PTHrP expression in bony invasive OSCC cells is driven by the 
transcription factor Gli2.  The expression of Gli2 requires both Hedgehog (Hh) and TGFβ 
signaling. In this study, we investigated how the tumor-bone microenvironment affects this Hh-
TGFβ/Gli2 signaling cascade, with the goal of identifying anti-tumor targets.  In both our work 
and that of others, levels of PTHrP significantly correlate with bony invasive status and are 
markedly increased at the tumor bone interface[90, 152]. 
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Since we have previously demonstrated in other tumor types that PTHrP and Gli2 expression are 
regulated by the bone microenvironment, we reasoned that the bone microenvironment may 
regulate Gli2 expression in invasive OSCC cells,[99, 100, 136, 153] and may contribute to the 
ability of OSCCs to invade the bone. One aspect of the bone that has been associated with the 
regulation of Gli2/PTHrP is the rigidity of the bone extracellular matrix (ECM) which is 1,000 
times more rigid than soft tissue[154]. Numerous reports highlight the contributions of a rigid 
ECM to increasing tumor progression and our group has shown that a rigid ECM regulates the 
bone-destroying phenotype of bone metastatic breast cancer[62]. Mechanotransduction allows 
cells to sense and respond to changes in the ECM by converting mechanical forces into 
biochemical signals[155]. A major regulator of both Gli2 and mechanical regulation is the primary 
cilia.  Canonical Hh signaling requires primary cilium to recruit and activate Gli proteins, 
suggesting that the increased activation of Gli2 is linked to the increase in ciliogenesis. In this 
study, we investigate how the rigid microenvironment regulates Gli2.  Here we show that OSCC 
cells require a rigid ECM to increase Gli2 activation and PTHrP expression. This mechanism 
occurs through mechanically transduced signaling, specifically at the levels of ROCK1/2 
activation and importantly, downstream to myosin. Surprisingly, cells grown on compliant 
matrices, with rigidities similar to collagen, do not respond to Hh or TGFβ stimulation. These 
results are specific to the Hh-TGFβ/Gli2 signaling axis, as protein levels of other pathways such 
as EGFR signaling remain unchanged across the two matrices.  Importantly, inhibiting 
mechanotransduction at the level of myosin prevents increases in both primary cilium and Gli2 
activation. Additionally, we find that bone rigid facilitates the expression of genes important for 
generating primary cilium, such as BBS1 and KIF3A.  Lastly, direct Gli2 inhibition using 
encapsulated GANT58 in vivo mimics the effects of compliant matrices, where tumor-bearing 
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mice treated with GANT58 show significantly decreased bone destruction and PTHrP expression. 
These studies demonstrate the important role of ECM rigidities on modulating Gli2 activation, and 
highlight the feasibility of using GANT58 in a localized delivery system to prevent OSCC invasion 
into the bone. 
Results 
Bone rigidity increases basal and stimulated expression of the osteolytic gene, PTHrP and its 
transcriptional activator, Gli2. While OSCC invasion into the mandible is associated with tumor 
recurrence and lower overall survival[33], very little is known about how OSCC cells respond to 
ECM rigidities similar to bone. To investigate this, we seeded OSCC cells onto 2D films with 
matrix rigidities matching collagen in the basement membrane (compliant) or cortical bone 
(rigid)[156]. Under serum free conditions, cells grown on rigid films significantly upregulated 
expression of Gli2 (Figure 16A) and PTHrP (Figure 16B) by qRT-PCR. Using Western Blots for 
nuclear Gli2, we also confirm that levels of active Gli2 protein is increased on rigid films as 
compared to compliant films (Figure 16C). To determine if these effects would be additive to 
stimulated levels of Gli2 and PTHrP, we used TGFβ to increase Gli2 activation and measured 
PTHrP expression by qRT-PCR. Surprisingly, OSCC cells grown on compliant films do not 
significantly increase PTHrP mRNA levels when stimulated with TGFβ (Figure 16D). This finding 
contrasts with cells grown on rigid films, which dramatically increase PTHrP mRNA expression. 
Additionally, Western Blots for EGFR, a commonly overexpressed oncogenic protein in 
OSCC[157], remains unchanged across both rigidities (Figure 16E), suggesting that the changes 
in gene expression due to rigidity are specific to the Hh-TGFβ/Gli2 signaling axis.  
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Extracellular matrix rigidity regulates OSCC response to Hh and TGFβ signaling modulation. 
To further investigate OSCC cellular responses to changes in rigidity, we treated cells with the Gli 
antagonist GANT58[137], and found that inhibiting Gli2 in cells grown on compliant films does 
not significantly alter PTHrP mRNA expression (Figure 17A). However, PTHrP mRNA 
expression is significantly reduced when cells grown on a rigid, bone-like film. We next examined 
the mechanism of Gli2 inhibition by GANT58 to better understand how changes in rigidity might 
Figure 16. Rigid matrices increase basal and stimulated expression of the osteolytic gene, PTHrP 
and its transcriptional activator, Gli2. OSCC cells grown on rigid (R) films in serum free media 
(SFM) significantly increase Gli2 expression (A) and PTHrP expression (B) by qRT-PCR, as 
compared to cells grown on compliant films (C). (C) OSCC cells grown on compliant films are unable 
to respond to TGFβ stimulation, while cells grown on rigid films significantly increase PTHrP 
expression by qRT-PCR. Cells grown on tissue culture poly-styrene (TCPS) increase PTHrP 
expression when stimulated, as expected. (D) Western blots for nuclear Gli2 protein demonstrate an 
increase in active Gli2 protein when cells are grown on rigid films as compared to compliant films 
under serum free conditions for 24 hours. (E) Changes in extracellular matrix rigidity does not 
modulate levels of EGFR.   As seen by Western Blot, OSCC cells grown on compliant or rigid films 
do not change levels of EGFR protein, suggesting that the effects of rigidity on increasing Gli2 are 
specific. 
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be affecting levels of Gli2 and PTHrP. OSCC cells stimulated with TGFβ and then treated with 
GANT58 significantly decrease levels of active Gli protein as compared to stimulated cells, as 
shown by luciferase activity using a Gli-binding site luciferase construct (Figure 17B graph). 
Additionally, by immunofluorescence, we observe a dramatic decrease in nuclear levels of Gli2 
(Figure 17B photos), suggesting that GANT58 prevents nuclear translocation of Gli2 as proposed, 
while also implying that rigidity increases Gli2 activity and nuclear localization. A similar increase 
in Gli2 nuclear translocation was also observed when OSCC cells plated on a rigid film were 
treated with TGFβ, but not when cells seeded on a compliant film were treated with TGFβ. TGFβ 
signaling is known to increase activation of Gli2 protein and expression of Gli2 mRNA through 
both canonical and non-canonical signaling[158]. Thus, we used the small molecule inhibitors to 
selective inhibit Smad 3 (SIS3) or MAPK (SB-202190) Targeting TGFβ signaling using either 
inhibitor decreased nuclear Gli2 proteins by Western blot (Figure 17C). Similarly, inhibition of 
canonical Hh signaling using cyclopamine in cells grown on rigid films decreases PTHrP mRNA 
expression (Figure 17D), indicating that rigidity can alter upstream signaling pathways that 
regulate Gli2 expression.  
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Inhibition of upstream mechanotransducers, αv integrins or Rho GTPases, does not prevent 
stimulated PTHrP expression on rigid films. To investigate the role of mechanotransduction on 
Gli2 and PTHrP modulation, we used cilengitide, a RGD pentapeptide inhibitor of αv integrins, to 
prevent integrin binding to the ECM. On compliant films, cells stimulated with TGFβ and treated 
with cilengitide do not significantly decrease Gli2 or PTHrP expression. Surprisingly, cells grown 
on rigid films and double treated with TGFβ and cilengitide do not significantly decrease Gli2 and 
PTHrP mRNA expression. In fact, we observe a significant increase in Gli2 and PTHrP expression 
as compared to the unstimulated control, which is similar to TGFβ only stimulated group (Figure 
Figure 17. Extracellular matrix rigidity regulates OSCC response to Hh and TGFβ signaling modulation 
(A) TGFβ stimulation is not sufficient to increase PTHrP in the absence of a rigid matrix.  
OSCC cells grown on compliant films are unable to increase PTHrP expression in response to TGFβ stimulation. 
On rigid films however, TFGB stimulation significantly increases PTHrP expression. (B) Furthermore, Gli2 
inhibition using GANT58 significantly reduces PTHrP expression, suggesting that the cellular effects of rigidity 
are upstream of Gli2. (C) TGFβ inhibition decreases Gli2 protein levels on rigid films. OSCC cells grown on 
compliant films show decreased nuclear Gli2 when treated with TFGB inhibitors. (D) Hh inhibition, using 
cyclopamine, decreases PTHrP expression in OSCC. OSCC cells grown on rigid films remain sensitive to 
canonical Hh inhibition, where Smoothened inhibition using cyclopamine prevents an increase in stimulated 
PTHrP levels 
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18A & 18B). Similar results are observed when OSCC cells are stimulated with TGFβ and treated 
with Rhosin, a selective reversible and potent inhibitor of RhoA GTPases (Figure 18C & 18D). 
We then used immunofluorescence staining to visualize levels of Gli2 protein in cells treated with 
Cilengitide or Rhosin (Figure 18E). Similar to the qRT-PCR data, neither integrin nor RhoA 
inhibition prevented stimulated PTHrP expression on rigid films. These results, though surprising, 
suggest that rigidity alters Gli2 and PTHrP expression independently of integrins and RhoA. 
 
 
Figure 18. Inhibition of upstream mechanotransducers, alpha 5 integrins and Rho GTPases, does 
not prevent stimulated PTHrP expression on rigid films. 
(A) OSCC cells grown on compliant films do not significantly change Gli2 expression in response to 
TGFβ stimulation with or without integrin inhibition. Conversely, on rigid films, integrin inhibition 
increases Gli2 expression. (B) OSCC cells grown on compliant films do not change levels of PTHrP in 
response to TGFβ stimulation nor integrin inhibition. On rigid films, integrin inhibition has no 
significant effect on PTHrP expression. (C) OSCC cells grown on compliant films do not change Gli2 
expression in response to RhoA inhibition. On rigid films, RhoA inhibition significantly increases Gli2 
mRNA levels. (D) OSCC cells grown on compliant films do not change PTHrP expression in response 
to RhoA inhibition. On rigid films, RhoA inhibition increases PTHrP mRNA levels. (E) Inhibition of 
integrins or RhoA does not prevent nuclear localization of Gli2 in OSCC cells treated with TGFβ and in 
some cells, leads to increased levels of active Gli2. 
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ROCK1/2 and non-muscle myosin II are required for PTHrP expression on rigid films. To 
determine if mechanical regulators downstream of integrin/RhoA activation could modulate Gli2 
and PTHrP levels, we investigated the contributions of ROCK1/2, a Rho associated kinase and 
downstream target of RhoA using the small molecule inhibitor Y-27632 to inhibit ROCK1/2 
activity.  ROCK1/2 inhibition did not significantly change Gli2 or PTHrP mRNA levels as 
measured by qRT-PCR on compliant or rigid films (Figure 19A), but on rigid films, ROCK1/2 
inhibition significantly decreased PTHrP, not Gli2, mRNA expression (Figure 19B). Western blots 
for nuclear Gli2 in cells treated with Y-27632 showed a significant decrease in active Gli2 when 
ROCK1/2 is inhibited, suggesting that ROCK1/2 only regulates Gli2 protein (Figure 19C). 
One of the effector proteins of mechanotransduction is non-muscle myosin II. This protein is 
downstream of ROCK1/2 and is responsible for actin and actomyosin rearrangement due to 
changes in ECM rigidities. To determine if non-muscle myosin II could modulate rigidity-
mediated expression of Gli2 and PTHrP, cells were treated with the myosin II inhibitor, 
blebbistatin.  Blebbistatin significantly decreased both Gli2 and PTHrP mRNA expression (Figure 
19D and 19E) and Gli activity using a Gli binding luciferase reporter construct (Figure 19F), 
similar to what was observed when cells were treated with GAN58.  These data suggest that bone-
like rigidity can stimulate a signaling cascade that facilitates Gli2 activation that is not activated 
on compliant matrices (soft tissue). 
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Bone rigidity increases expression of ciliogenesis related genes. To investigate the link between 
myosin-mediated cytoskeletal rearrangement in response to ECM rigidity and Gli2 activation, we 
next measured levels of primary cilium. The primary cilium is known to both initiate and respond 
to changes in the ECM rigidity[159]. Additionally, the primary cilium is required for canonical Hh 
signaling[160]. Thus, we used qRT-PCR to measure mRNA levels of three genes associated with 
primary ciliogenesis, IFT88, BBS1, and KIF3A. Under serum-free conditions, BBS1 and KIF3A 
expression was significantly higher on rigid films as compared to compliant films, while IFT88 
Figure 19. Downstream mechanotransducers, ROCK and Myosin II, are required for PTHrP 
expression on rigid films 
(A) OSCC cells grown on compliant or rigid films do not significantly change Gli2 expression in response 
to TGFβ stimulation or ROCK inhibition. (B) OSCC cells grown on compliant films do not change levels 
of PTHrP in response to TGFβ stimulation nor ROCK inhibition. On rigid films however, ROCK 
inhibition significantly decreases PTHrP expression. (C) While ROCK inhibition does not change Gli2 
mRNA levels by qRT-PCR, by Western Blot Y-27632 decreases levels of nuclear Gli2 in OSCC cells 
stimulated with TGFβ. (D) OSCC cells grown on compliant films do not change Gli2 expression in 
response to myosin II inhibition. On rigid films however, myosin II inhibition significantly decreases Gli2 
mRNA levels. (E) OSCC cells grown on compliant films do not change PTHrP expression in response to 
myosin II inhibition. On rigid films however, myosin II inhibition significantly decreases PTHrP mRNA 
levels. (F) Myosin II inhibition significantly decreases Gli2 protein activity in OSCC cells stimulated with 
Ihh, similar to the Gli2 antagonist, GANT58. 
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levels trended, but did not significantly change (Figure 20A).  To determine if changes in 
mechanotransduction correlated with ciliogenesis, we used blebbistatin to inhibit myosin II, which 
led to significantly reduced numbers of primary cilium (Figure 20B). We then plated cells onto 
either rigid of compliant 2D films and used blebbistatin to inhibit myosin II before measuring 
changes in ciliogenesis gene expression to determine if mechanical signaling inhibition affected 
ciliogenesis. Surprisingly, on compliant films, myosin inhibition significantly increases KIF3A 
expression, while IFT88 and BBS1 were not significantly different (Figure 20C). On rigid films 
however, myosin inhibition significantly decreases IFT88, BBS1, and KIF3A mRNA expression 
(Figure 20D). These results demonstrate that the importance of mechanical signaling proteins on 
increasing ciliogenesis.  
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Figure 20. Rigid extracellular matrices increase expression of ciliogenesis genes and inhibition of 
mechanotransduction prevents stimulated ciliogenesis. 
(A) OSCC cells significantly increase expression of ciliogenesis genes, BBS1 and KIF3A (but not IFT88) 
on rigid versus compliant films.  (B) OSCC cells grown on compliant films increase levels of KIF3A, but 
not IFT88 or BBS1 when myosin activity is inhibited with blebbistatin. (C) OSCC cells grown on rigid 
films significantly decrease levels of KIF3A, IFT88 and BBS1 when myosin activity is inhibited with 
blebbistatin. (D) OSCC patient samples show an increase in ciliogenesis genes in tumors that have invaded 
the bone as compared to tumors that have only invaded soft tissue. (E) OSCC patient samples show an 
increase in levels of primary cilium and Gli2 in tumors that have invaded the bone as compared to tumors 
that have only invaded soft tissue. (F) OSCC cells grown on rigid films increase levels of primary cilium 
in response to rigidity, which facilitates Gli2 activation and PTHrP expression downstream. 
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Clinical OSCC samples with bony invasion show increased levels of focal adhesion kinases as 
compared to samples with no bony invasion. To determine the clinical relevance of these findings, 
we used the cBioPortal to determine if bony invasion correlates with mechanical signaling. In 
OSCC, we have found that the Hh-TGFβ/Gli2/PTHrP signaling axis is essential for bony invasion, 
and it is well known that activation of FAK, RhoA, and ROCK is important for mechanical 
signaling. Analyzing patient samples in cBioPortal, we found that Gli2 and PTHrP mRNA gene 
expression significantly correlates with ROCK2 and FAK respectively (Figure 21) in bony 
invasive OSCC. These results suggest that bony invasion in OSCC is correlated with the activation 
of mechanical signaling molecules in patient samples.  
  Gli2 inhibition, using GANT58-loaded microspheres significantly prevents osteolytic signaling 
and subsequent bone loss. Our in vitro findings suggest that mechontransduction inhibitors may 
be useful to prevent bony invasion in OSCC. However, existing inhibitors have poor 
pharmacokinetic profiles or quickly become ineffective[161]. Since Gli2 remains the essential 
modulating protein controlling bony invasion in OSCC, we chose to target Gli2 using GANT58 in 
a semi-orthotopic model of mandibular invasion. Targeting Gli2 has two main advantages.  Since 
Gli2 activity is absent in many adult tissues[75], we anticipate fewer off-target effects. 
Additionally, because GANT58 directly targets Gli protein, there is a lower chance of acquired 
Co-occurrence of Gene A and Gene B in 530 HNSCC samples (Modified from cBioPortal) 
Gene A Gene B p-value 
PTK2 PTHLH 0.004 
Figure 21. Clinical OSCC samples with bony invasion show increased levels of focal adhesion kinases as 
compared to samples with no bony invasion FAK (PTK2) significantly correlates with PTHrP (PTHLH) in a cohort 
of 530 HNSCC samples suggesting that FAK is important for bony invasion in OSCC. 
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resistance to Hh inhibition, unlike current Smo inhibitors[162, 163]. Unfortunately, GANT58 is 
difficult to administer in biologically relevant doses due to its hydrophobic nature. To address this 
limitation, GANT58 was loaded into poly-propylene sulfide (PPS) microspheres that degrade in 
the presence of cell-secreted reactive oxygen species[164, 165], which is commonly elevated at 
the tumor microenvironment. Incubation of GANT58 microspheres in 0.02 – 3% H2O2 resulted in 
a dose-responsive release of the drug (Figure 22A & 22B). OSCC cells were injected into the 
masseter muscle of male athymic mice and allowed to progress for ten days, at which time, 
GANT58 loaded or empty (control) microspheres were injected directly into the tumor site two to 
three times weekly for four weeks. High-resolution x-rays of dissected mandibles were used to 
quantify the area of bone loss. Mice treated with GANT58 microspheres had a significantly smaller 
total lesion area compared to mice treated with empty microspheres (Figure 23A). Additionally, 
µCT analyses of the mandibles showed that GANT58 treatment significantly prevented bone loss 
(Figure 23B). Histological analyses demonstrate a significant decrease in osteoclasts and PTHrP 
levels, demonstrating that Gli2 inhibition using GANT58 microspheres significantly prevents 
osteolytic signaling and subsequent bone loss (Figure 23C and 23D). 
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Figure 22. (A) Size distribution histogram of microsphere diameter of over 100 samples based on SEM 
images. Results indicated an average diameter of 4.2 μm with a standard deviation of 3 μm. Scale bar in 
SEM representative image is 50 μm. (B) In vitro ROS-dependent release kinetics of GANT58 from the 
PPS microspheres in the presence of H2O2 concentrations ranging from 0 to 3 wt%. Microspheres exhibit 
an H2O2 dose-dependent release over a 28-day period. 
A. 
B. 
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Discussion 
Our studies have demonstrated that in OSCC, that bone-like rigidity can alter the expression of 
genes associated with bone destruction by activating the Hh-TGFβ/Gli2/PTHrP signaling axis. 
When OSCCs are grown on compliant matrices (basement membrane), they are unable to stimulate 
Gli2 expression. However, on rigid matrices (bone tissue), cells dramatically increase Gli2 and 
PTHrP levels. We demonstrate that this activation of Gli2 is driven by mechanical signaling, which 
can facilitate the formation of primary cilium, leading to an increase in Gli2 activation and 
subsequently PTHrP expression (Figure 23E).  
Figure 23. Gli2 inhibition using GANT58 decreases PTHrP expression and bony invasion in vivo  
(A) Male athymic mice treated with GANT58 loaded microparticles show a significant decrease in lesion 
area by high resolution x-ray. (B) Similarly, mice treated with GANT58 loaded microparticles have 
significantly more bone volume as compared to the control mice. Importantly, non-tumor bearing mice 
treated with GANT58 microparticles have bone volumes similar to that of mice treated with control 
particles. (C) Mice treated with GANT58 microparticles also show decreased levels of TRAP positive 
multi-nucleated cells as well decreased levels of PTHrP positive staining (D). (E) Proposed mechanism 
of bone rigidity mediated OSCC invasion. 
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The primary cilium is a complex organelle known to function as a mechanosensor and 
mechanotransducer[166-168]. While this is known to occur via calcium signaling, other pathways, 
such as Hh and PDGF signaling, also play a role[169, 170]. Additionally, primary cilium formation 
depends on, among other things, the organization and assembly of various cytoskeletal proteins 
and filaments. While tubulin is the main component of primary cilium, actin organization as well 
as myosin activity status also play important roles in ciliogenesis[171-173]. Furthermore, the 
activity and orientation of the cytoskeleton is itself dependent on the rigidity of the ECM[174, 
175]. This suggests that primary cilium is not only important for cells to respond to ECM rigidity, 
but proper ciliogenesis may also dependent on it. This dynamic positive feedback loop integrates 
the role of ECM rigidity to increasing levels of primary cilium and thus canonical Hh signaling.  
Currently, there are no published studies investigating the regulatory role of bone extracellular 
matrix rigidity on OSCC invasion. Recent reports have highlighted the contributions of ECM 
proteins such as fibronectin and thrombospondin, on increasing the invasive and metastatic 
potential of OSCC[22, 97]. In these studies, mechanical signaling via integrin and downstream 
Rho activation are responsible for initiating signaling cascades important for NK-kB signaling. In 
our studies, we specifically investigated the role of bone mimicking ECM on increasing bone-
invasion potential. While the contribution of Rho/ROCK signaling was demonstrated to be 
important for increasing Gli2 and PTHrP levels, additional work is needed to understand how these 
signaling systems are activated upstream. In our system, cilengitide treatment to inhibit αv 
integrins was unable to decrease bony invasion, suggesting that other mechanotransducers are 
involved. Hippo network signaling, specifically at the level of YAP and TAZ, is the likely mediator 
converting mechanical cues into biochemical signaling cascades in bony invasive OSCC. In the 
last decade, significant strides have been made to understand canonical and non-canonical 
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YAP/TAZ regulation. In fact, several groups have identified YAP/TAZ nuclear localization when 
cells are grown on rigid 2D or 3D substrates[176, 177]. On rigid substrates, YAP/TAZ is shuttled 
into the nucleus, where it activates gene expression. On compliant substrates, however, YAP/TAZ 
remains trapped in the cytosol, where it is inactive[178]. While we did not directly investigate 
Hippo network signaling, its role as a mechanosensing and mechanotransducing signaling system 
suggests that it is likely playing a role in our system as well[179, 180]. Existing research 
investigating mandibular invasion of OSCC has yet to translate into actionable targets to prevent 
bony invasion. However, our findings support a targeted and viable approach to prevent bony 
invasion by using newer local delivery systems. Engineered particles, on the micro and nano scale, 
are useful to increase drug retention and uptake[181]. Additionally, the use of these particles 
allows for solubilization of drugs that would otherwise be difficult to administer in physiologically 
relevant doses. GANT58 for example, though efficacious in vitro, is too non-polar to be used in 
physiological doses. We show, for the first time, that in a relevant pre-clinical animal model of 
mandibular invasion, encapsulated GANT58 can be used to prevent bony invasion of OSCC tumor 
cells. This key experiment extends the application of Gli2 inhibition to all subtypes of OSCC that 
express Gli2 and PTHrP using both canonical and non-canonical Hh signaling. These results can 
also be extended beyond OSCC. Several other tumor types that use Hh signaling as a driver of 
tumorigenesis, such as medulloblastoma and osteosarcoma, can be targeted using Gli2 
inhibitors[182]. Additionally, unlike current Hh inhibitors that target Smo, GANT58 inhibits the 
final Hh effector protein Gli which is much less likely to lead to acquired resistance. Collectively, 
these findings demonstrate the feasibility of using locally delivered Gli2 inhibitors to prevent 
rigidity-mediated tumor-induced bone destruction in OSCC patients and should be evaluated 
further as a possible adjuvant targeted treatment. 
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Materials and Methods 
Cell lines 
The OSCC cell lines SCC4 and CAL27 were used as described. Cell lines were cultured in 50% 
Dulbecco’s modification of Eagle’s medium and 50% Nutrient Mixture F12 (DMEM/F12) 
(ThermoFisher Scientific), supplemented with 10% fetal bovine serum (FBS) (Hyclone 
Laboratories) and 1% penicillin/streptomycin (Mediatech). Cells were maintained at 37°C with 
5% CO2. 
Drug Treatments 
All drug treatments were carried out in serum free DMEM/F12 for 24 hours. TGFβ was used at 
10ng/mL. TGFβ buffer (5%BSA in 4mmol HCl) was used as a control. GANT58 (Sigma-Aldrich) 
was used at 10μM. Ihh and SIS3 (EMD Millipore) were used at 25ng/mL and 10μM respectively. 
Cyclopamine (LC Labs) was used at 12nM. SB202190 (Tocris) was used at 10μM. Y-27632 
(Sigma) was used at 20μM. Cilengitide (SelleckChem) was used at 100nM. Rhosin (Calbiochem) 
was used at (30 µM). Blebbistatin (Tocris) was used at 2μM.  
Transfections/ Luciferase Assays 
Cells were transfected per manufacturer’s instructions using Lipofectamine 2000 (ThermoFisher 
Scientific). Briefly, cells were incubated overnight in Opti-Mem (ThermoFisher Scientific) before 
being transfected at a ratio of 1.25 µg DNA to 1 µl Lipofectamine 2000. All cells were transfected 
with the Gli reporter plasmid and the pRL Renilla Luciferase control reporter plasmid (Promega) 
at a ratio of 3:1. Fresh media containing drug treatments and antibiotics was added to cells the 
following morning. Cells were harvested 24 hours later and luciferase activity measured using the 
Dual-Luciferase Assay System (Promega) and the 20/20n Luminometer (Turner Biosystems). 
Quantitative real-time PCR 
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Cells were harvested by direct lysis and total RNA extracted using the RNeasy Mini Kit (Qiagen). 
The qScript cDNA synthesis kit (Quanta, VWR) was used to synthesize cDNA from 1ug RNA. 
Validated Taq-Man primers from (ThermoFischer Scientific) were used to measure gene 
expression in triplicate (from a minimum sample number of n=3) using the 7500 Real-Time PCR 
System from Applied BioSciences (ThermoFisher Scientific). Absolute gene expression was 
quantified using a standard curve and 18S was used as an internal control. 
Antibodies 
Primary Antibodies: Gli2 (Novus Biologicals) 1:500, Histone H3 (Abcam) 1:200, EGFR (Abcam) 
1:5000, GAPDH (Cell Signaling) 1:10 000, PTHrP (Jack Martin) 1:4, acetylated tubulin (Sigma) 
50ng/ml. Unlabeled goat IgG and rabbit IgG from Santa Cruz (1:400) were used as control primary 
antibodies. 
Secondary Antibodies for Western Blots and IHC: Anti-mouse IgG HRP (Advansta) 1:25 000, 
Anti-goat IgG HRP (Santa Cruz) 1:5000, Anti-rabbit IgG HRP (Santa Cruz) 1:5000 
Secondary Antibodies for IF: Alexa Flour 488 anti-rabbit IgG (Life Technologies) 1:2000, Alexa 
Flour 594 anti-mouse (Life Technologies) 2 drops/ml. 
Western Blots 
Briefly, cell lysate was harvested using RIPA Buffer (Sigma) supplemented with protease and 
phosphatase inhibitors (Roche). Nuclear and cytoplasmic extracts were separated using NE-PER 
(Pierce) and lysates were quantified using the BCA Protein Assay Kit (Pierce). 10-15ug of protein 
were loaded per well and gels were run using Nu Page supplies (Novex by Life Technologies) 
before being transferred to PVDF membranes. Membranes were blocked in TBS with .1% Tween-
20 and 5% BSA or 5% non-fat dry milk for 2 hours. Primary antibody incubations were done 
overnight at four degrees under gentle agitation, and secondary antibodies were incubated for one 
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hour at room temperature under gentle agitation. Membranes were exposed using Western 
Lightening Plus-ECL (Perkin Elmer). 
Clinical OSCC Samples 
Dr. Kim Ely reviewed patient charts to identify OSCC patients that underwent a mandibulectomy 
as compared to those that underwent soft tissue removal which was used to purchase 16 matching 
cyrosections from the Vanderbilt-Baker Head and Neck Bio-repository.  
Immunofluorescence Staining 
Cells were fixed for 20 minutes in 4% formaldehyde, then permeabilized for five minutes in .1% 
Triton X-100 (Sigma) before blocking in 5% BSA. Primary antibodies were used overnight at four 
degrees. Secondary antibodies were used for one hour at room temperature. Cells were stained 
with DAPI (100ng/ml) or TO-PRO®-3 (1 µM) to distinguish nuclei before being cover-slipped 
for imaging.  
Microsphere characterization 
Microspheres were generated as described [31]. GANT58-loaded microspheres were size 
characterized using SEM and had an average molecular diameter of 4.2 ± 3 μm. An average 
diameter greater than 4 μm was imperative to discourage macrophage phagocytosis of the 
microsphere. A sufficient microsphere size was achieved by using a 0.5% PVA solution as a 
stabilizer during the microsphere fabrication process as well as adjusting the homogenization time 
to 45 seconds. The loading and encapsulation efficiency were determined using a fluorescence 
plate reader and the fluorescence of GANT58 after being dissolved in DMSO for a 24-hour period. 
The loading and encapsulation efficiency was determined to be 14% and 25%, respectively, using 
established formulas as described.  
Animal Studies 
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All animal studies were carried out in compliance with the Vanderbilt University Institutional 
Animal Care and Use Committee and the National Institutes of Health guidelines.            
Masseter muscle injections: 1x106 cells were injected into the right and left masseter muscle 
(parallel to the mandible) of 4-6-week-old athymic male mice from Harlan Laboratories. Tumor 
control mice received PBS injections. Drug treatments began once tumors were palpable (~10 
days) which consisted of 50-75 µl injections of ~5mg/kg GANT58 loaded microparticles or empty-
PPS microparticles as controls. Mice were weighed weekly to assess tumor burden and provided 
with soft food (Diet Gel, Clear H20) ad libitum. All mice were sacrificed after 28 days and 
mandibles were dissected for ex vivo analyses. The XR-60 digital radiography system from 
Faxitron was used to acquire high-resolution images from dissected mandibles. 
Immunohistochemical Staining 
Mandible specimens were dissected and fixed in 10% neutral-buffered formalin (Fisher Scientific) 
for 48 hours at four degrees. Mandibles were then decalcified in 10% EDTA for 10 days at room 
temperature under gentle agitation and then embedded in paraffin. Mandible sections (5-7μm 
thickness) were stained with hematoxylin & eosin, orange G, and phloxine to measure tumor 
burden. Antibody staining against Gli2/PTHrP was used to measure Gli2/PTHrP protein 
expression. HRP linked rabbit anti-goat or goat anti-rabbit (Santa Cruz) and ImmPACT NOVA 
RED from Vector Laboratories were used to visualize staining. TRAP staining was used to 
measure osteoclast numbers. All slides were examined under an Olympus microscope at 20X and 
40X and images (taken using Olympus DP71 camera and software) were quantified using 
Metamorph software (Molecular Devices, Inc.) for thresholding and region of interest analysis.  
Immunohistochemistry/Immunofluorescence Analyses 
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Histological images were uploaded into Metamorph. For each image, the bottom incisor was used 
as a landmark. The area of tumor was traced using region of interest analyses, then, positive 
staining was quantified for each slide using a representative threshold (based on the positive 
control). For PTHrP, positive staining is marked by tumor specific brown staining. For Gli2, 
positive staining is marked by tumor specific nuclear brown staining. Non-specific staining from 
the IgG control was used measure background staining. This value was subtracted from each slide 
to normalize values. The resulting value represents positive staining, which is then divided by the 
total area of the image yielding percent positive staining.  
Statistical analyses 
All in vitro experiments were done in triplicate with a minimum n =3 samples. All in vivo 
experiments were done with a minimum of n=8 mice per group. All statistical analyses were done 
using InStat v3.03 software from GraphPad Software. Significance is presented as asterisks, where 
* denotes p<.05, ** denotes p<.01 and *** denotes p<.001. 
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CHAPTER IV 
CONCLUSIONS AND DISCUSSION 
OSCC remains a significant clinical problem globally. While understanding factors that cause 
OSCC has led to improved prevention methods (such as dental screening and smoking cessation 
programs), patients afflicted with the disease continue to have limited treatment options and poor 
prognoses[6]. EGFR inhibition in OSCC, using Cetuximab, was a highly anticipated targeted 
treatment option and is in fact the first FDA approved targeted treatment for HNSCC. 
Unfortunately, like may targeted treatments, drug tolerance and tumor relapse develops in many 
OSCC patients. In fact, although 75% of HNSCC over-express EGFR, clinical trials have 
demonstrated that Cetuximab alone is mostly beneficial in cases of metastatic disease, and in some 
staging groups does not increase progression free survival[28, 30]. Recently, HPV related 
increases in carcinoma of the head and neck (particularly in men ages 30 -40) has garnered much 
attention in the media and has increased awareness of the disease. However, HPV induced HNSCC 
mostly develops in the oropharynx (which is not included in the oral cavity) and actually show 
better response rates to treatments, increasing overall survival. Unfortunately, this is not the case 
with OSCC, as many patients show tumor relapse and decreased overall survival. While EGFR is 
often overexpressed in OSCC, it is now generally accepted that EGFR amplification is not a 
common driver of tumorigenesis in OSCC patients, though it certainly contributes to tumor 
progression. Current clinical trials in OSCC seek to investigate possible synergistic treatment 
effects with Cetuximab in combination with different classes of chemotherapy/radiation and/or 
another immunotherapy, namely PD-1. Research in OSCC has identified other genes important for 
OSCC, with a few (such as the p53 superfamily), being implicated as a driver mutation. OSCC 
sequencing studies however, do not show consistent mutated/upregulated genes that could also  
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serve as reliable targets. Additionally, many OSCC tumors demonstrate signaling plasticity as 
opposed to oncogene addition, where many patients fail to respond to Cetuximab in an appreciable 
amount even though tumor biopsies stain positive for EGFR. The field of OSCC research has 
seemed to acknowledged that OSCC initiation and progression is multifactorial and several groups 
have demonstrated the importance of personalized therapy based on the gross genetic differences 
not only between different OSCC patient tumors (derived from sequencing data), but also within 
tumors themselves. Without improvements in targeted treatment options however, improvements 
in survival for OSCC seem unlikely. 
Hh/Gli Signaling Axis  
 The work presented in this text demonstrates some of the signaling plasticity observed in other 
OSCC tumors. Importantly however, it contributes to the body of knowledge surrounding OSCC 
signaling mechanisms. For OSCC invasion into the bone, this is especially important as there have 
been very few studies investigating this subset of OSCC. In Appendix C, we have shown that bony 
invasion and bone destruction is controlled by Hh and TGFβ signaling, which are required to 
increase Gli2 expression and protein activity and PTHrP expression and protein levels in OSCC. 
Additionally, beta-catenin has the potential to regulate Gli2 and PTHrP, but Wnt signaling is 
dysregulated in OSCC. This signaling system requires functional mechanical signaling, where 
rigid matrices increase ciliogenesis in a Rho/Rock/myosin dependent manner. Increased 
ciliogenesis leads to an increase in canonical Hh signaling which is at the apex of Gli protein 
regulation in OSCC. Bony invasion and bone destruction can be significantly decreased by 
targeting Gli protein, the effector molecule of this osteolytic signaling system, using GANT58 
loaded microparticles. This work demonstrates the central role of Hh signaling, specifically Gli2 
on regulating PTHrP, an essential osteolytic signaling molecule in OSCC.  
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Gli role in invasion. Gli2 in OSCC is known to correlate with tumor progression and poor patient 
prognoses[75]. Our studies indicate that targeting Gli2 would be beneficial to reduce bony invasion 
and bone destruction in patients. Patients without mandibular involvement may also benefit from 
Gli2 inhibition. In the infiltrative OSCC line, CAL27, we used shRNA to stably knock-down Gli2 
expression. Different clones of CAL27 cells with repressed Gli2 expression were used in an MTT 
assay to measure cell viability and no significant differences in cell viability between any clones 
and the transfection control CAL27 cells were observed. However, when shGli2 CAL27 cells are 
injected into the masseter muscle of athymic male mice, a distinct phenotype was observed. 
CAL27 cells with repressed Gli2 expression had significantly lower levels of soft tissue invasion 
into the muscle, which was the site of tumor injection. In some mice, there was no observable 
tumor take or the tumors were very small, not well vascularized and not attached to the muscle 
tissue. (Appendix D) We have also found the opposite to be true, where Gli2 protein 
overexpression in SCC4 significantly increases PTHrP expression. In vivo however, SCC4 cells 
overexpressing Gli2 present as mixed (osteoblastic and osteoclastic) lesions, making analyses 
difficult to interpret. Appendix E shows no significant difference in the degree of anisotropy, or 
organization, in the long bones of tumor bearing mice. Additionally, although we observed greater 
bone loss in the Gli2 over expressing group, there was also increased new bone formation denoted 
by the starburst pattern of bone by x-ray (Appendix F). These findings highlight the role of Gli2 
on mediating invasion and bone destruction in OSCC. We have found similar results in vitro using 
the Gli antagonist GANT58. CAL27 cells were used in migration and invasion assays, where 
CAL27 cells are seeded in serum-free medium in chambers on top of a porous membrane with 
serum-containing medium in the chambers below. Under these conditions cells migrate downward 
through the pores into the serum- containing medium. When GANT58 is added to the cells seeded 
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in serum-free medium, cells are still able to migrate in similar numbers as control cells, suggesting 
that GANT58 does not play a major role in mediating tumor cell migration. However, to model 
invasion, a thin layer of serum reduced Matrigel was coated onto the porous membrane, requiring 
cells to first invade through the Matrigel layer before migration through the pores. This invasion 
is an active process, as cells have to secrete factors, such as MMP’s (Appendix G) to degrade the 
crosslinked proteins of the Matrigel layer. Cells grown on Matrigel in serum-free medium invade 
as small clusters of cells to the bottom chamber. However, when transfected to express shRNA 
against Gli2, cells are unable to invade through the Matrigel (Appendix H). These findings 
demonstrate the importance of Gli signaling for invasion in vitro and can be used to extrapolate 
mechanisms behind similar observation in vivo. 
Implications of Gli targeting. The functional consequence of Gli in OSCC invasion (both bony 
and non-bony) suggests that Gli inhibition would be beneficial in OSCC patients. We propose the 
use of GANT58 to inhibit Gli activity to prevent bony invasion, though there are clear applications 
for its use in soft tissue invasion as well. Gli expression is silenced in most adult tissues, although 
can be found in basal/stem-cell compartments, making Gli2 a better target due to less anticipated 
side effects. There are currently no direct Gli inhibitors on the market, though inhibitors to its 
upstream regulator Smo have been, and continue to be, developed. Unlike Smo, which develops 
several drug resistant mutations before and after treatment, Gli is highly conserved and is not 
expected to develop actionable mutations. One caveat of Gli inhibition using GANT58 centers 
around unintended targets. Gli2 is one of three Gli proteins (Gli1, Gli2 and Gli3). While Gli3 is 
structurally distinct and functions as a transcriptional repressor, Gli1 and Gli2 are very similar and 
are both targets of GANT58. This may be beneficial, as Gli2 inhibition alone may lead to a 
compensatory upregulation of Gli1contributing to drug resistance and treatment failure. In this 
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case, Gli1 and Gli2 inhibition ensures that downstream Gli targets are effectively silenced. 
However, targeting both proteins also means that cell compartments that actively use Hh signaling, 
such as in the stem cell niche of the hair follicle[183], would be deregulated leading to possible 
negative side effects. In OSCC however, Gli1 mRNA is not detectable in several cell lines. We 
postulate that in these cells, Gli1 remains silenced as it should be in normal adult tissues and has 
not been induced oncogenically. OSCC cell lines transfected to express Gli1 also do not show an 
increase in PTHrP expression, supporting that in OSCC, Gli2 is the regulator of PTHrP expression. 
Another major caveat of GANT58 treatment to inhibit Gli is drug delivery. GANT58 is highly 
polar and is unable to be delivered to the tumor in appreciable quantities. Our group has overcome 
this limitation by loading free GANT58 drug into microparticles that disassemble in hypoxic 
environments, similar to what is seen at the tumor microenvironment. In our system, microparticles 
are   delivered directly to the tumor site, where they serve as a drug depo and release GANT58 as 
needed. This delivery mechanism works well for clearly visible and/or more superficial tumors. 
Invasive tumors that are not easily seen however, would be harder to treat, like those found on the 
floor of the mouth. 
Gli inhibition using GANT58 to prevent bony invasion would not be done as a single agent. In 
athymic male mice bearing CAL27 tumors treated with GANT58, tumors grew to be similar in 
size as those treated with the control microparticles.  To this end, GANT58 should be paired with 
an antitumor treatment to decrease tumor burden while also preventing bony invasion. Based on 
our findings, there may be synergistic applications of inhibiting Gli in vivo. Several groups have 
attempted to understand which genes are mutated in OSCC to determine if there exists a genetic 
signature in OSCC that can be used to stratify tumor drivers, tumor types, treatment options, and 
prognoses. While these studies have not directly identified Hh/Gli signaling molecules, genes that 
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have the potential to regulate Gli have been identified. This includes Ras signaling and beta-
catenin. Both of these studies investigated gene mutations, and included Smo in their gene panels. 
It is important to note however that wild-type Smo can function as a potent oncogene and 
demonstrates mutational resistance after drug treatment, which was not controlled for in these 
studies. Additionally, using cBioPortal, we observe that from a 528-sample cohort, 15% of samples 
show Gli2 alteration. Strikingly, only three of the 15% demonstrated mutations, with the resulting 
12% being upregulation and/or amplification of the Gli2 gene. These results highlight the 
limitation of investigating a mutagenic phenotype in a system where the presence/absence of a 
gene is just as, if not more, important. 
TGFβ Signaling in Bony Invasion. 
In our work, we specifically investigated other signaling systems that have the ability to regulate 
Gli2, at the level of transcriptional control as well as protein, independently of canonical Hh 
signaling. TGFβ signaling, which is known to regulate PTHrP expression via Smad/MapK 
activation is also active in OSCC[66]. Our work demonstrates the contribution of Smad2/3 
overexpression on increasing PTHrP expression quite dramatically. We have observed functional 
Smad signaling is also important for cell viability (Appendix I), where Smad3 inhibition decreases 
cell viability 50% after just 24 hours. MapK is essential as well, since p38/MapK inhibition using 
SB202190 significantly decreased stimulated PTHrP expression. The question remains, however, 
if Smad2/3 regulates PTHrP via Gli2. Existing work demonstrates functional Smad binding sites 
on the promoter region of PTHrP, suggesting that TGFΒ  may be able to regulate PTHrP 
expression independently of Gli2. However, it is also known that there are functional Smad2/3 
binding sites on the Gli2 promoter as well. We have observed, using luciferase reporter assays that 
Gli2 promoter activity is significantly increased when TGFβ signaling is active. This suggests that 
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TGFβ may directly increase Gli2 expression and may also directly and indirectly increase PTHrP 
expression. Based on existing information and because of the sequential and connected roles of 
this signaling system, the extensive experiments required to delineate precisely if and how TGFβ 
signaling activates Gli2 and PTHrP are not warranted.  
Wnt Signaling in Bony Invasion. 
Hh signaling and Wnt signaling have been known to cross-talk in development, and in our system, 
a similar observation has been made. While Wnt signaling in OSCC appears to be dysregulated, 
downstream activation of beta-catenin and Wnt related targets have been shown. In OSCC it is not 
clear if upstream Wnt receptors Frizzled and Lrp are functional. Endpoint PCR for LRP5/6 
expression showed the presence of LRP5/6 mRNA in erosive SCC4 cells. Treatment with lithium 
chloride however did not have a measurable effect on PTHrP mRNA expression. By qRT-PCR 
lithium chloride treatment also did not increase DKK1, a well-known Wnt target gene that should 
be transcriptionally activated in response to active canonical Wnt signaling. Interestingly, TGFβ 
treatment in SCC4 cells led to a threefold increase in DKK1 mRNA expression. Although Wnt 
activation using lithium chloride had no measurable effect, one possible explanation for this 
observation may be the concentration of lithium chloride needed may have been different from 
that given to the SCC4 cells. This possibility is unlikely though, as SCC4 cells were treated with 
one, five, and ten micro molar concentrations of lithium chloride to measure PTHrP expression 
using luciferase reporter assays which showed no significant differences in PTHrP promoter 
activity with or without lithium chloride treatment. An additional experiment was used to test 20 
micro molar and 40 micro molar concentrations of lithium chloride on increasing PTHrP mRNA 
by qRT-PCR (which also showed similar results). While it is unlikely that higher dosages are 
required to activate Wnt signaling, there are several possibilities for these observations that can be 
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investigated. Firstly, although SCC4 cells express LRP5/6 mRNA, it is not known whether the 
LRP5/6 receptors are actually present on the cell surface, and if they are whether they are 
functional/mutated or not. Additionally, the presence and/or levels of the receptor Frizzled was not 
investigated. Wnt signaling in OSCC is probably mutated/dysregulated, which is in line with 
reports of Wnt signaling molecules in patient samples. Evidence for this is seen in SCC4 cells 
treated with Sclerostin, which is a Wnt inhibitor that binds directly to the Wnt receptor LRP. SCC4 
cells treated with Sclerostin significantly increase PTHrP expression, more so than TGFβ 
stimulation, which suggests that Wnt signaling is active but abnormal. These findings do not rule 
out the possibility of Wnt signaling silencing downstream of the receptor, since we have not yet 
been able to measure increased beta-catenin levels/activation with upstream Wnt modulation. 
Additional experiments investigating whether Wnt signaling can be activated with receptor based 
stimulation are still needed to understand the status of Wnt signaling in OSCC. One plausible 
explanation is that Wnt signaling is inactive in OSCC. Our experiments modulating beta-catenin 
represent exogenous expression of a form of beta-catenin that is not easily degraded. Thus, beta-
catenin regulation of Gli2 and PTHrP that we have observed may represent a possible signaling 
avenue for OSCC as compared to an existing one.  
Mechanical Signaling in Bony Invasion. 
Finally, the regulation potential of bone rigidity demonstrates a novel role of ECM rigidity on 
increasing Hh signaling in OSCC. We have found that rigid matrices increase the osteolytic 
potential of OSCC by supporting ciliogeneis and thus, Gli activation. Based on our previous work 
investigating osteolytic signaling in triple negative breast cancer, we reasoned that in OSCC, 
extracellular signaling proteins that respond to changes in the ECM would be indispensable for 
our observed phenotype. Integrins are one of the main responders to ECM rigidity and the OSCC 
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cell lines used express several classes of integrins. However, OSCC cells treated with cilengitide 
to inhibit αv integrins remained responsive to TGFβ and significantly increased PTHrP expression. 
Integrin regulation however, makes it difficult to determine the status of integrin activity when 
cells are treated with cilengitide. Integrin inhibition can have profound effects on integrin protein 
levels, protein activity, and even gene expression, and it has been previously demonstrated that 
these events are not always correlative. For example, in glioblastoma (where cilengetide was used 
in clinical trials) data from basic research demonstrated that cilengitide could greatly reduce levels 
on integrins in the cell. Unfortunately, patients on cilengitide had poor responses and progressed 
rapidly, even though cilengitde levels were indeed lower. Later it was revealed that although 
protein levels were lower in cilengitide treated patients/cells, protein activity was similar to that of 
the untreated controls. This finding was essential to understanding the mechanism of resistance 
but is also context specific. In a bone-metastatic clone of the triple negative breast cancer cell line, 
MDA-MB-231, cilengitide treatment significant decreases integrin β3 expression. In OSCC 
treated with cilengitide, downstream activation of ROCK 1 was not significantly different from 
the control group. One plausible explanation for this observation is that in the integrin 
expression/activity profile in OSCC has not yet been explored. What is known though, is that 
another integrin receptor, integrin α5β1 is also capable of binding to the ECM of the rigidity 
models used in our experiments and importantly, is not a target of the αv inhibitor, cilengitde. 
Additional experiments investigating expression/activity levels of this integrin would be required 
to better understand the findings we observed. Similarly, to cilengitde treatment, RhoA inhibition 
using Rhosin did not prevent TGFβ induced expression of PTHrP. Here however, Rhosin treatment 
decreased levels of the downstream target ROCK1 by Western blot, suggesting that RhoA was 
inhibited as expected. We reason that the downstream activation of mechanical signaling that we 
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observed is probably not through the expected signaling cascade of integrins and RhoA. We 
speculate that other mechanosensitive signaling mechanisms, such as Hippo signaling with 
effector molecules YAP and TAZ, could be playing a role and should be investigated further[176, 
177]. Regardless of the upstream activators, we expect an increase in activation of focal adhesion 
kinases once mechanical signaling is active. Data from the cBioPortal demonstrates a significant 
correlation between FAK gene expression and PTHrP in a large cohort of HNSCC patients. While 
this data suggests an important correlation between matrix rigidity and osteolytic signaling, gene 
expression does not always correlate with protein levels and more importantly, protein activity. To 
investigate this, we measured levels of FAK and active, phosphorylated FAK in a small cohort of 
OSCC patients. While the data trended, due to small sample size (n=12 total) and staining 
localization variability, FAK/pFAK was not found to correlate with bony invasion. Interestingly, 
some patients showed intense staining at the periphery of the tumor, while others showed diffuse 
staining throughout and still others showed intense staining in the adjacent stroma. These results 
were unexpected and confounded data analysis. Literature on this observation suggests that 
differential FAK/pFAK activation serves as a prognostic tool for tumor progression, especially in 
the context of invasion[184-186]. While we were unable to study this phenotype in greater depth, 
FAK/pFAK localization may prove to be informative to characterize different invasion patterns of 
OSCC in the future.  
Ciliogenesis gene expression and numbers of primary cilia, were increased on bone-like 
matrices and dependent on mechanical signaling, respectively. The primary cilium is essential for 
canonical Hh signaling and though it is well studied in development and physiological settings, it 
is much less understood in cancer. In OSCC, primary cilium seems to be regulated as expected, 
since use of HPI-4 to inhibit ciliogenesis led to smaller numbers of primary cilia by 
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immunofluorescence and decreased expression of Gli targets by an EMT qRT-PCR array 
(Appendix J). In our system, it is not known what regulators are important for ciliogenesis gene 
expression, but we surmise that they are downstream or secondary targets of mechanical signaling. 
The osteolytic signaling system observed in OSSC grown on matrices with bone-like rigidities is 
dependent on engineered two-dimensional films of synthetic material, which presents a distinct set 
of challenges. Cells on compliant matrices take much longer (>3x longer) to adhere to the matrix 
when plated, as compared to cells grown on rigid films. In addition, cells grown on rigid matrices 
are phenotypically different, appearing larger, more uniform, and more “connected” with other 
cells in appearance. These clear phenotypic differences suggest that signaling systems between 
these groups may also be different. One bonus of using engineered 2D matrices is that the two 
rigidities are identical, in composition, but are tunable over a wide range of rigidities. Additionally, 
while we adsorb fibronectin to the 2D films to facilitate cell adhesion when plating, the ECM 
priotein can easily be replaced to match a range of cell specific needs.  The rigidity dependent 
phenotype observed in these studies parallels the observation that once OSCC invades into the 
mandible, tumors progress, excess bone is resorbed and patients suffer from poor quality of life 
and shorter survival times. Importantly, this work demonstrates the feasibility of targeting the 
central regulator of OSCC invasion into bone, Gli2. These finding contribute substantially to the 
current knowledge of mechanisms controlling bony invasion. Before this work, these signaling 
systems were not shown to play a role in OSCC invasion. With this added body of knowledge, 
additional research, investigating the efficacy of Gli2 targeted treatment to prevent bony invasion, 
is warranted. 
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Future Directions 
GANT58 loaded defect supports. The long-term goal of this project is to use the elucidated 
signaling mechanisms controlling bony invasion and bone destruction in OSCC as a basis for 
targeted treatments for patients at risk for recurrence of mandibular involvement. To do this, we 
propose a two-step approach to structurally support the mandible as well as prevent bony invasion. 
We have used 2D polyurethane films in vitro to modulate ECM rigidities, but we can also generate 
polyurethane matrices in 3D, using a 3D printer. Using uCT imaging, these scaffolds are almost 
perfect replicas of the normal resected bone and can be constructed in near micron scale. 
Additionally, by changing the composition of the starting materials to include polylactic acid, we 
can make 3D scaffolds that can be resorbed by osteoclasts. This becomes especially important 
when exogenous factors are embedded into the 3D scaffolds. We plan to fabricate 3D scaffolds 
containing lyophilized GANT58 to be used in vivo. We plan to experiment with also embedding 
growth factors to aid in healing and anti-tumor drugs to prevent tumor growth.  Our preliminary 
experiments suggest that this plan is feasible (Appendix K), and warrants investigation. If 
successful, these findings can be used for the first targeted therapy to prevent bony invasion and 
bone destruction in OSCC patients.  
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APPENDIX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix A: Gli2 loss in CAL27 cells does not significantly affect viability. CAL27 cells 
transfected to stably express shRNA against Gli2 show varied, although not significant, 
differences in viability by MTT assay. 
Appendix B: Purmorphamine treatment transiently increases PTHrP expression. SCC4 cells were 
treated with Gli activators TGFβ or purmorphamine along with Actinomyosin D to prevent 
transcription. PTHrP mRNA were measured using qRT-PCR and showed a potent, but transient 
increase of after stimulation. TGFβ stimulation is expected to increase PTHrP mRNA expression 
at later time points. 
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Appendix C: Mechanism of bony invasion and bone destruction in OSCC. Bony invasion and bone destruction is 
controlled by Hh and TGFβ signaling, which are required to increase Gli2 expression and protein activity and 
PTHrP expression and protein levels in OSCC. Additionally, beta-catenin has the potential to regulate Gli2 and 
PTHrP, but Wnt signaling is dysregulated in OSCC. This signaling system requires functional mechanical 
signaling, where rigid matrices increase ciliogenesis in a Rho/Rock/myosin dependent manner. Increased 
ciliogenesis leads to an increase in canonical Hh signaling which is at the apex of Gli protein regulation in OSCC. 
Bony invasion and bone destructed can be significantly decreased by targeting Gli protein, the effector molecule 
of this osteolytic signaling system, using GANT58 loaded microparticles. 
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Appendix D: Loss of Gli2 in CAL27 cells reduces bony invasion and tumor size in vivo. 
CAL27 cells stably transfected to express shRNA against Gli2 were injected into the 
masseter muscle of male athymic mic and allowed to progress. Control tumors are larger 
and have invaded into the muscle tissue (black arrows) while tumors in the shGli2 group 
are much smaller and non-invasive (red arrows). 
Appendix E: SCC4 control and Gli2 SA662 cells have similar degrees of 
anisotropy. SCC4 cells stably transfected to express Gli2 SA662 were injected 
into the tibiae of male athymic mic and allowed to progress. While Gli2 SA662 
tumors showed greater tumor progression, uCT analysis demonstrate similar 
levels of bone disorganization. 
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Appendix F: SCC4 Gli2 SA662 tumors cause mixed lesions in vivo. SCC4 cells stably 
transfected to express Gli2 SA662 were injected into the tibiae of male athymic mic and allowed 
to progress. When compared to non-transfected SCC4 and CAL27 tumors, SCC4 Gli2 SA662 
mice show both bone destruction and new bone formation, which resembles starburst patterning. 
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Appendix G: MMP14 Levels in OSCC. qRT-PCR shows that SCC61 and SCC4 express 
significantly more MMP14 than SCC1352 and CAL27 at basal levels.  
Appendix H: CAL27 shGli2 invasion.  Using Matri-Gel coated transwells, less CAL27 cells, 
stably transfected to express shRNA against Gli2, are able to invade, as compared to control 
transfected cells. 
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Appendix I: CAL27 MTT Assay with SIS3 treatment. CAL27 cells treated with a selective 
inhibitor of Smad3 for 24hours show 50% less viability at the indicated treatment 
concentrations. 
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Appendix J: CAL27 PCR Array with ciliogenesis inhibition. CAL27 cells treated with the 
ciliogenesis inhibitor HPI-4 for 24hours decreased EMT gene expression. Several of the 
downregulated targets belong to the Hh/Gli signaling family (i.e. SNAI and ZEB) 
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Appendix K: Mandibular defect repair in rats. In a non-survival feasibility study, full thickness 
defects were drilled through rat mandibles before being filled with an injectable, settable 
polyurethane composite. Cross sectional uCT images are also shown. 
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